Track market-moving stories before they get noisy

Danica Pension Livsforsikringsaktieselskab purchased a new position in Wells Fargo & Company (NYSE:WFC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 212,859 shares of the financial services provider’s stock, valued at approximately $17,591,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Godfrey Financial Associates Inc. acquired a new stake in Wells Fargo & Company during the 4th quarter worth $25,000. Miller Capital Partners Inc. purchased a new position in shares of Wells Fargo & Company in the fourth quarter worth about $25,000. Navalign LLC acquired a new position in Wells Fargo & Company during the fourth quarter worth about $26,000. Joseph Group Capital Management acquired a new position in Wells Fargo & Company during the fourth quarter worth about $28,000. Finally, Phillip James Consulting Co. purchased a new stake in Wells Fargo & Company during the 1st quarter valued at about $28,000. 75.90% of the stock is owned by institutional investors and hedge funds.

Wells Fargo & Company Trading Down 0.0% Shares of Wells Fargo & Company stock opened at $83.83 on Monday. The stock has a 50 day moving average of $86.08 and a 200 day moving average of $82.91. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.90 and a current ratio of 0.90. The firm has a market capitalization of $253.50 billion, a price-to-earnings ratio of 12.18, a PEG ratio of 0.91 and a beta of 0.92. Wells Fargo & Company has a fifty-two week low of $72.78 and a fifty-two week high of $97.76.

Wells Fargo & Company (NYSE:WFC – Get Free Report) last posted its earnings results on Tuesday, July 14th. The financial services provider reported $1.96 EPS for the quarter, beating analysts’ consensus estimates of $1.73 by $0.23. Wells Fargo & Company had a return on equity of 13.85% and a net margin of 17.55%.The company had revenue of $22.62 billion for the quarter, compared to the consensus estimate of $21.86 billion. During the same quarter in the previous year, the business earned $1.60 earnings per share. The company’s revenue for the quarter was up 8.6% on a year-over-year basis. As a group, research analysts predict that Wells Fargo & Company will post 7.26 earnings per share for the current year. Wells Fargo & Company Increases Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, August 7th will be issued a $0.50 dividend. This is an increase from Wells Fargo & Company’s previous quarterly dividend of $0.45. The ex-dividend date is Friday, August 7th. This represents a $2.00 annualized dividend and a yield of 2.4%. Wells Fargo & Company’s payout ratio is presently 29.07%.

Analyst Upgrades and Downgrades A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. raised their target price on shares of Wells Fargo & Company from $93.50 to $95.50 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Morgan Stanley lifted their price objective on Wells Fargo & Company from $97.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Monday, June 29th. Robert W. Baird upped their target price on Wells Fargo & Company from $85.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Phillip Securities upgraded Wells Fargo & Company from a “moderate buy” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, UBS Group lowered their price target on shares of Wells Fargo & Company from $105.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Wells Fargo & Company has a consensus rating of “Moderate Buy” and a consensus target price of $98.61.

Get Our Latest Stock Analysis on Wells Fargo & Company

Wells Fargo & Company Profile (Free Report)

Wells Fargo & Company is a diversified, U.S.-based financial services company headquartered in San Francisco, California. Founded in 1852 by Henry Wells and William G. Fargo, the firm has evolved from its origins in express delivery and pioneer-era banking into one of the largest full-service banks in the United States. The company provides a broad range of financial products and services to individual, small business, commercial, and institutional clients. Charles W. Scharf serves as chief executive officer.

Wells Fargo operates across several core business segments, including consumer banking and lending, commercial banking, corporate and investment banking, and wealth and investment management.

See Also Five stocks we like better than Wells Fargo & Company VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding WFC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wells Fargo & Company (NYSE:WFC – Free Report).

Receive News & Ratings for Wells Fargo & Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wells Fargo & Company and related companies with MarketBeat.com's FREE daily email newsletter.

United Parcel Service is investing more than $2 billion into its business across its international, healthcare and supply chain solutions businesses, the company told CNBC exclusively on Monday.

The ongoing investments began in 2024 and will continue through 2028, but UPS said it had not previously disclosed the total investment. The shipping giant said the aim is to help businesses move faster and stay adaptable to changing macroeconomic pressures and global supply chain disruptions.

"These investments are really aligned to one of our big strategic areas of focus, which is creating capabilities to enable our customers, particularly in complex industries, to more effectively run their global supply chains," Scott Szwast, vice president of international strategy, told CNBC.

Some of the projects under the investment include a new hub in the Philippines this year, a new Canadian facility opening next year in Ontario and a new air hub at Hong Kong International Airport in 2028.

UPS has launched a tech-enabled logistics center in Taiwan and a supply chain solutions facility in Amsterdam that combines freight, brokerage and cold-chain solutions. Szwast said the new logistics center in Taiwan has been able to leverage automation and robotics to increase the total supply chain speed by a day.

The logistics company also said it now has flights running five times a week between Paris and Hong Kong and between Shenzhen, China, and Sydney to meet growing demand.

Szwast said as global supply chains get more complicated, certain global markets, like those across Asia, are becoming more important for companies than they were before.

"What they find in a lot of cases is that their supply chains look more like their histories than their strategies," he said. "They need very agile, very effective solutions to connect these new parts of their businesses. They need a lot of optionality and a lot of flexibility, and that's what we're investing in."

UPS also recently announced a $48 million investment into 27 temperature-controlled facilities across its network to supplement its healthcare initiatives, including the shipment of temperature-sensitive medications like GLP-1 drugs. That announcement came as logistics companies around the globe are racing to stay ahead of growing demand in niche areas like cold-chain storage.

Especially as macroeconomic pressures disrupt global supply chains, Szwast said, businesses have been increasingly trying to ensure they don't have "all their operational eggs in one basket." At the same time, those companies are also innovating new products with new shipping needs at rates not seen before, he added.

Szwast said the investments will help UPS differentiate its end-to-end logistics offerings, ensuring the logistics company can equip businesses from the first step to the last step of the shipping process.

"We're investing to give them tailored capabilities aligned to the needs of their specific industries that cover the markets they're increasingly sourcing from and distributing to, and do it in a way that they can make commitments to their customers," Szwast said.

Great Lakes Advisors LLC purchased a new stake in Realty Income Corporation (NYSE:O – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 9,764 shares of the real estate investment trust’s stock, valued at approximately $605,000.

Several other large investors have also recently bought and sold shares of O. DGS Capital Management LLC boosted its holdings in shares of Realty Income by 4.3% during the fourth quarter. DGS Capital Management LLC now owns 3,836 shares of the real estate investment trust’s stock worth $216,000 after acquiring an additional 158 shares during the period. Tactive Advisors LLC grew its position in shares of Realty Income by 1.8% in the second quarter. Tactive Advisors LLC now owns 9,239 shares of the real estate investment trust’s stock valued at $572,000 after purchasing an additional 163 shares during the last quarter. Patrick M Sweeney & Associates Inc. grew its position in shares of Realty Income by 4.5% in the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 3,801 shares of the real estate investment trust’s stock valued at $214,000 after purchasing an additional 164 shares during the last quarter. CYBER HORNET ETFs LLC increased its stake in shares of Realty Income by 7.4% during the fourth quarter. CYBER HORNET ETFs LLC now owns 2,417 shares of the real estate investment trust’s stock worth $136,000 after purchasing an additional 166 shares during the period. Finally, First National Trust Co increased its stake in shares of Realty Income by 1.2% during the fourth quarter. First National Trust Co now owns 15,109 shares of the real estate investment trust’s stock worth $852,000 after purchasing an additional 180 shares during the period. 70.81% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades O has been the subject of several recent research reports. UBS Group set a $67.00 price target on Realty Income in a research note on Thursday, June 18th. Scotiabank lowered their price objective on Realty Income from $72.00 to $67.00 and set a “sector outperform” rating on the stock in a research report on Thursday, June 18th. Barclays dropped their target price on Realty Income from $68.00 to $67.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Weiss Ratings raised shares of Realty Income from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Finally, Freedom Capital upgraded shares of Realty Income from a “hold” rating to a “strong-buy” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.42.

View Our Latest Research Report on O Key Headlines Impacting Realty Income Here are the key news stories impacting Realty Income this week:

Positive Sentiment: Analysts at Yahoo Finance argue that Realty Income could be approximately 12% undervalued following its recent convertible-note activity. The company’s monthly dividend, supported by an indicated yield of roughly 5.2%, remains a key attraction for income-focused investors. Realty Income Could Be 12% Undervalued Following New Convertible Note Issues Positive Sentiment: Investment commentary continues to favor Realty Income as a dependable dividend stock because of its monthly payment schedule, relatively high yield, and recurring net-lease rental income. Other coverage also highlights its European expansion as a potential long-term growth engine. Why I Think the Best Dividend Stock Isn’t a Tech Name: It’s Realty Income Neutral Sentiment: Realty Income completed or announced offerings totaling approximately $1.625 billion of convertible senior notes due 2031, including notes carrying a 3.750% coupon. The financing could improve liquidity and support acquisitions, but its equity-linked structure may increase future share dilution and adds to the company’s financing obligations. Realty Income Adds $1.625 Billion of Convertible Notes Due 2031 Neutral Sentiment: Articles continue to list Realty Income among monthly dividend payers and emphasize that investors may need roughly $19,000 to $20,000 invested to generate $1,000 in annual dividends at current yield levels. These reports reinforce income demand but do not materially change company fundamentals. 5 Monthly Dividend Payers to Own Heading Into September Negative Sentiment: The new debt has likely contributed to near-term caution because investors must assess additional leverage, interest costs, and possible dilution from conversion. Realty Income’s recent short-term performance has also been weak, increasing pressure on the stock despite its dividend appeal. Realty Income Stock Up 0.0% NYSE O opened at $62.61 on Monday. The company has a current ratio of 5.88, a quick ratio of 5.88 and a debt-to-equity ratio of 0.73. Realty Income Corporation has a 1-year low of $55.86 and a 1-year high of $67.93. The company has a 50 day moving average of $63.18 and a 200-day moving average of $63.17. The company has a market cap of $59.24 billion, a price-to-earnings ratio of 45.70, a PEG ratio of 4.44 and a beta of 0.71.

Realty Income (NYSE:O – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The real estate investment trust reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Realty Income had a return on equity of 3.12% and a net margin of 20.93%.The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the prior year, the business posted $1.05 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. Realty Income has set its FY 2026 guidance at 4.440-4.450 EPS. On average, equities research analysts expect that Realty Income Corporation will post 4.43 earnings per share for the current fiscal year.

Realty Income Announces Dividend The business also recently announced a monthly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Monday, August 31st will be issued a dividend of $0.271 per share. This represents a c) annualized dividend and a dividend yield of 5.2%. The ex-dividend date of this dividend is Monday, August 31st. Realty Income’s dividend payout ratio is 237.23%.

Realty Income Profile (Free Report)

Realty Income Corporation (NYSE: O) is a real estate investment trust (REIT) that acquires, owns and manages commercial properties subject primarily to long-term net lease agreements. The company’s business model focuses on generating predictable, contractual rental income by leasing properties to tenants under agreements that typically place responsibility for taxes, insurance and maintenance on the tenant. Realty Income is publicly traded on the New York Stock Exchange and markets itself as a reliable income-oriented REIT.

Realty Income’s portfolio is concentrated in single-tenant, retail and service-oriented properties such as drugstores, convenience stores, dollar and discount retailers, restaurants, and other essential-service businesses.

Featured Articles Five stocks we like better than Realty Income VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding O? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Realty Income Corporation (NYSE:O – Free Report).

Receive News & Ratings for Realty Income Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Realty Income and related companies with MarketBeat.com's FREE daily email newsletter.

The U.S. Food and Drug Administration has cleared Roche (ROPC.S) and partner Eli Lilly's (LLY.N) blood test to help ​identify signs of Alzheimer's disease in people aged ‌55 and older with cognitive decline.

The test, Elecsys pTau217, is a biomarker blood test that can help doctors identify patients who are ​likely or unlikely to have Alzheimer's-related brain changes, ​Roche said on Monday.

The FDA clearance follows European ⁠approval for the test in May.

The test can be ​run on more than 4,500 Roche laboratory analyzers already installed ​across the United States, which the company said could help broaden access.

Separately, Labcorp (LH.N) and Quest Diagnostics (DGX.N) said that they plan to offer ​the test through their laboratory networks, potentially expanding availability ​across the United States.

Roche did not disclose the test's price.

Current methods to ‌detect ⁠amyloid, a protein linked to the disease, typically rely on positron emission tomography or PET scans or cerebrospinal fluid testing, which can be expensive, invasive and less widely ​available.

The FDA clearance ​comes as ⁠drugmakers and diagnostic companies race to develop simpler tests for Alzheimer's disease amid growing ​demand for earlier diagnosis and treatment.

Fujirebio's Lumipulse became ​the ⁠first blood test cleared by the FDA to aid in the assessment of Alzheimer's disease in 2025.

Elecsys pTau217 is not ⁠intended ​to be used as a standalone ​diagnostic test and results should be interpreted alongside other clinical information, Roche ​said.

Boston Trust Walden Corp raised its stake in Broadcom Inc. (NASDAQ:AVGO – Free Report) by 338.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,948 shares of the semiconductor manufacturer’s stock after buying an additional 83,335 shares during the period. Boston Trust Walden Corp’s holdings in Broadcom were worth $40,777,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fullerton Advisors LLC boosted its position in Broadcom by 1.3% during the first quarter. Fullerton Advisors LLC now owns 1,989 shares of the semiconductor manufacturer’s stock worth $616,000 after purchasing an additional 25 shares in the last quarter. NORTHSTAR ASSET MANAGEMENT Co increased its position in shares of Broadcom by 0.5% in the first quarter. NORTHSTAR ASSET MANAGEMENT Co now owns 5,350 shares of the semiconductor manufacturer’s stock valued at $1,656,000 after buying an additional 25 shares in the last quarter. RFG Holdings Inc. boosted its position in shares of Broadcom by 0.3% in the 1st quarter. RFG Holdings Inc. now owns 8,499 shares of the semiconductor manufacturer’s stock worth $2,631,000 after buying an additional 26 shares in the last quarter. Yukon Wealth Management Inc. grew its stake in Broadcom by 1.1% in the 1st quarter. Yukon Wealth Management Inc. now owns 2,501 shares of the semiconductor manufacturer’s stock valued at $774,000 after acquiring an additional 26 shares during the last quarter. Finally, NerdWallet Wealth Partners LLC grew its stake in Broadcom by 2.6% in the 2nd quarter. NerdWallet Wealth Partners LLC now owns 1,057 shares of the semiconductor manufacturer’s stock valued at $399,000 after acquiring an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 76.43% of the company’s stock.

Broadcom Stock Performance Shares of NASDAQ AVGO opened at $368.45 on Monday. The company has a 50-day simple moving average of $388.57 and a 200-day simple moving average of $375.10. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.24 and a quick ratio of 2.01. The company has a market cap of $1.75 trillion, a PE ratio of 61.41, a price-to-earnings-growth ratio of 0.70 and a beta of 1.45. Broadcom Inc. has a 12 month low of $287.17 and a 12 month high of $495.00.

Broadcom (NASDAQ:AVGO – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The semiconductor manufacturer reported $2.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.04. Broadcom had a net margin of 38.85% and a return on equity of 41.61%. The business had revenue of $22.19 billion for the quarter, compared to the consensus estimate of $22.13 billion. During the same quarter in the prior year, the firm posted $1.58 earnings per share. The company’s quarterly revenue was up 47.9% compared to the same quarter last year. On average, equities analysts anticipate that Broadcom Inc. will post 10.24 earnings per share for the current year. Broadcom Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Monday, June 22nd were paid a dividend of $0.65 per share. This represents a $2.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Monday, June 22nd. Broadcom’s dividend payout ratio is currently 43.33%.

More Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: AI financing deal could expand Broadcom’s growth opportunity: Broadcom is reportedly discussing $70 billion to $80 billion of debt financing—potentially approaching $100 billion—to provide AI chips to Anthropic and other companies. The arrangement could support substantial future chip demand, although the financing remains under discussion. Broadcom debt deal expected to reach upwards of $70 billion Positive Sentiment: Analysts remain constructive: BMO initiated coverage with an “outperform” rating and a $455 price target, implying meaningful upside from recent levels. Other recent commentary also argues that Broadcom’s AI cycle and long-term custom-chip position could support further gains. Broadcom Stock Picks Up Another Lofty Bull Note Positive Sentiment: Strong AI demand underpins the bullish case: Reports cite approximately $30 billion in quarterly AI bookings and management’s goal of exceeding $100 billion in AI sales by 2027. Broadcom’s latest reported quarter also showed 47.9% year-over-year revenue growth, reinforcing the company’s momentum. Broadcom’s AI Boom: Is a 2x Stock Gain Still Within Reach? Neutral Sentiment: Debt-funded expansion introduces execution and balance-sheet risk: Borrowing tens of billions of dollars could accelerate AI infrastructure growth, but it would also increase leverage and financing costs if customer demand or deal economics disappoint. Broadcom reportedly eyes nearly $100 billion debt package Negative Sentiment: Marvell’s Google partnership threatens Broadcom’s custom AI-chip dominance: Marvell’s agreement covers products connected to Google’s TPU ecosystem, including inference accelerators and networking components. Google also received warrants that could align it more closely with Marvell, raising concerns about future share loss for Broadcom despite Broadcom’s existing multiyear Google partnership. Marvell Constructs an AI Moat With Alphabet Warrants Analyst Ratings Changes AVGO has been the subject of a number of research reports. Wall Street Zen cut shares of Broadcom from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $515.00 price objective (up from $430.00) on shares of Broadcom in a research note on Thursday, June 4th. Cantor Fitzgerald restated an “overweight” rating and set a $525.00 price objective on shares of Broadcom in a research report on Thursday, June 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $535.00 target price (up from $450.00) on shares of Broadcom in a research note on Thursday, June 4th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $545.00 target price (up from $430.00) on shares of Broadcom in a report on Thursday, May 14th. Twenty-nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $491.97.

View Our Latest Research Report on AVGO

Insiders Place Their Bets In related news, Director Gayla J. Delly sold 1,890 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $385.38, for a total value of $728,368.20. Following the completion of the transaction, the director directly owned 31,326 shares in the company, valued at approximately $12,072,413.88. This represents a 5.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Mark David Brazeal sold 25,000 shares of Broadcom stock in a transaction on Friday, July 10th. The shares were sold at an average price of $401.33, for a total transaction of $10,033,250.00. Following the completion of the transaction, the insider owned 194,989 shares in the company, valued at approximately $78,254,935.37. This trade represents a 11.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,644 shares of company stock worth $24,016,214 in the last three months. Company insiders own 1.90% of the company’s stock.

Broadcom Profile (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Recommended Stories Five stocks we like better than Broadcom VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding AVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Broadcom Inc. (NASDAQ:AVGO – Free Report).

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Cornerstone Capital Inc. bought a new stake in Broadcom Inc. (NASDAQ:AVGO – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,715 shares of the semiconductor manufacturer’s stock, valued at approximately $648,000.

Several other hedge funds also recently bought and sold shares of the company. ROSS JOHNSON & Associates LLC increased its stake in shares of Broadcom by 1,320.0% during the 4th quarter. ROSS JOHNSON & Associates LLC now owns 71 shares of the semiconductor manufacturer’s stock worth $25,000 after purchasing an additional 66 shares during the last quarter. SWAN Capital LLC lifted its stake in shares of Broadcom by 261.9% in the 4th quarter. SWAN Capital LLC now owns 76 shares of the semiconductor manufacturer’s stock valued at $26,000 after purchasing an additional 55 shares during the last quarter. Networth Advisors LLC lifted its stake in shares of Broadcom by 546.2% in the 1st quarter. Networth Advisors LLC now owns 84 shares of the semiconductor manufacturer’s stock valued at $26,000 after purchasing an additional 71 shares during the last quarter. Nvest Wealth Strategies Inc. bought a new stake in Broadcom in the fourth quarter worth $33,000. Finally, Cherry Tree Wealth Management LLC boosted its holdings in Broadcom by 44.9% in the fourth quarter. Cherry Tree Wealth Management LLC now owns 129 shares of the semiconductor manufacturer’s stock worth $45,000 after purchasing an additional 40 shares in the last quarter. 76.43% of the stock is owned by institutional investors and hedge funds.

More Broadcom News Here are the key news stories impacting Broadcom this week:

Positive Sentiment: AI financing deal could expand Broadcom’s growth opportunity: Broadcom is reportedly discussing $70 billion to $80 billion of debt financing—potentially approaching $100 billion—to provide AI chips to Anthropic and other companies. The arrangement could support substantial future chip demand, although the financing remains under discussion. Broadcom debt deal expected to reach upwards of $70 billion Positive Sentiment: Analysts remain constructive: BMO initiated coverage with an “outperform” rating and a $455 price target, implying meaningful upside from recent levels. Other recent commentary also argues that Broadcom’s AI cycle and long-term custom-chip position could support further gains. Broadcom Stock Picks Up Another Lofty Bull Note Positive Sentiment: Strong AI demand underpins the bullish case: Reports cite approximately $30 billion in quarterly AI bookings and management’s goal of exceeding $100 billion in AI sales by 2027. Broadcom’s latest reported quarter also showed 47.9% year-over-year revenue growth, reinforcing the company’s momentum. Broadcom’s AI Boom: Is a 2x Stock Gain Still Within Reach? Neutral Sentiment: Debt-funded expansion introduces execution and balance-sheet risk: Borrowing tens of billions of dollars could accelerate AI infrastructure growth, but it would also increase leverage and financing costs if customer demand or deal economics disappoint. Broadcom reportedly eyes nearly $100 billion debt package Negative Sentiment: Marvell’s Google partnership threatens Broadcom’s custom AI-chip dominance: Marvell’s agreement covers products connected to Google’s TPU ecosystem, including inference accelerators and networking components. Google also received warrants that could align it more closely with Marvell, raising concerns about future share loss for Broadcom despite Broadcom’s existing multiyear Google partnership. Marvell Constructs an AI Moat With Alphabet Warrants Wall Street Analyst Weigh In Several equities analysts have commented on AVGO shares. JPMorgan Chase & Co. increased their target price on shares of Broadcom from $500.00 to $580.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Mizuho boosted their price target on Broadcom from $480.00 to $530.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Evercore reiterated an “outperform” rating and set a $582.00 price target on shares of Broadcom in a research note on Tuesday, May 19th. TD Cowen reissued a “buy” rating and set a $500.00 price objective on shares of Broadcom in a report on Thursday, June 4th. Finally, Citigroup reissued a “buy” rating on shares of Broadcom in a research note on Thursday, June 4th. Twenty-nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $491.97. Check Out Our Latest Analysis on AVGO

Broadcom Price Performance NASDAQ AVGO opened at $368.45 on Monday. The stock has a 50-day simple moving average of $388.57 and a 200 day simple moving average of $375.10. Broadcom Inc. has a twelve month low of $287.17 and a twelve month high of $495.00. The stock has a market capitalization of $1.75 trillion, a PE ratio of 61.41, a P/E/G ratio of 0.70 and a beta of 1.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.01 and a current ratio of 2.24.

Broadcom (NASDAQ:AVGO – Get Free Report) last released its earnings results on Wednesday, June 3rd. The semiconductor manufacturer reported $2.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The firm had revenue of $22.19 billion for the quarter, compared to analyst estimates of $22.13 billion. Broadcom had a return on equity of 41.61% and a net margin of 38.85%.The company’s revenue was up 47.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 EPS. Research analysts anticipate that Broadcom Inc. will post 10.24 EPS for the current year.

Broadcom Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Monday, June 22nd were given a $0.65 dividend. This represents a $2.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Monday, June 22nd. Broadcom’s dividend payout ratio is currently 43.33%.

Insider Activity at Broadcom In other news, Director Justine Page sold 1,602 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $373.86, for a total value of $598,923.72. Following the sale, the director owned 17,426 shares in the company, valued at approximately $6,514,884.36. This trade represents a 8.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gayla J. Delly sold 1,890 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $385.38, for a total transaction of $728,368.20. Following the transaction, the director directly owned 31,326 shares in the company, valued at $12,072,413.88. This trade represents a 5.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 61,644 shares of company stock worth $24,016,214. Insiders own 1.90% of the company’s stock.

About Broadcom (Free Report)

Broadcom Inc (NASDAQ: AVGO) is a global technology company that designs, develops and supplies semiconductor and infrastructure software solutions for a broad range of markets. The company’s semiconductor business provides components and systems for wired and wireless communications, enterprise and cloud storage, networking and broadband access, serving original equipment manufacturers, cloud service providers, telecommunications carriers and industrial customers worldwide. Broadcom is headquartered in Irvine, California, and operates globally with research, development and sales organizations across North America, Europe and Asia.

On the semiconductor side, Broadcom’s portfolio includes system-on-chip (SoC) and application-specific integrated circuit (ASIC) solutions, radio-frequency and connectivity components, Ethernet switching and PHY devices, storage adapters and controllers, optical transceivers and other networking silicon.

Recommended Stories Five stocks we like better than Broadcom VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Broadcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Broadcom and related companies with MarketBeat.com's FREE daily email newsletter.

Biondo Investment Advisors LLC bought a new stake in Illinois Tool Works Inc. (NYSE:ITW – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 43,436 shares of the industrial products company’s stock, valued at approximately $11,748,000. Illinois Tool Works comprises about 1.4% of Biondo Investment Advisors LLC’s investment portfolio, making the stock its 27th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Cresta Advisors Ltd. acquired a new position in shares of Illinois Tool Works during the 4th quarter valued at about $25,000. Motiv8 Investments LLC acquired a new position in Illinois Tool Works during the fourth quarter worth approximately $27,000. Kemnay Advisory Services Inc. purchased a new position in shares of Illinois Tool Works in the 4th quarter worth $27,000. Ares Financial Consulting LLC purchased a new stake in Illinois Tool Works during the fourth quarter valued at about $31,000. Finally, Wilkerson Advisory Group LLC increased its stake in Illinois Tool Works by 77.6% during the first quarter. Wilkerson Advisory Group LLC now owns 119 shares of the industrial products company’s stock worth $31,000 after acquiring an additional 52 shares during the last quarter. 79.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illinois Tool Works In related news, CAO Matteo C. Pigozzo sold 277 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $289.22, for a total transaction of $80,113.94. Following the transaction, the chief accounting officer owned 3,394 shares in the company, valued at $981,612.68. This trade represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jennifer F. Scanlon bought 806 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was purchased at an average price of $247.99 per share, with a total value of $199,879.94. Following the completion of the transaction, the director directly owned 1,652 shares of the company’s stock, valued at $409,679.48. This trade represents a 95.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.83% of the stock is owned by company insiders.

Wall Street Analyst Weigh In Several equities analysts have recently weighed in on ITW shares. Weiss Ratings raised Illinois Tool Works from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Evercore reduced their target price on shares of Illinois Tool Works from $296.00 to $272.00 in a report on Monday, May 11th. Truist Financial increased their price objective on shares of Illinois Tool Works from $280.00 to $301.00 and gave the company a “hold” rating in a research report on Thursday, July 2nd. The Goldman Sachs Group restated a “sell” rating and issued a $254.00 price target on shares of Illinois Tool Works in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. upped their price target on shares of Illinois Tool Works from $310.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $281.25. View Our Latest Report on Illinois Tool Works

Illinois Tool Works Price Performance ITW opened at $282.23 on Monday. The company has a quick ratio of 0.81, a current ratio of 1.11 and a debt-to-equity ratio of 2.26. The company’s 50-day moving average price is $278.00 and its 200 day moving average price is $271.55. Illinois Tool Works Inc. has a fifty-two week low of $238.82 and a fifty-two week high of $303.15. The firm has a market cap of $80.38 billion, a price-to-earnings ratio of 25.59, a price-to-earnings-growth ratio of 4.77 and a beta of 0.99.

Illinois Tool Works (NYSE:ITW – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The industrial products company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.80 by $0.04. The business had revenue of $4.30 billion for the quarter, compared to analysts’ expectations of $4.19 billion. Illinois Tool Works had a return on equity of 101.72% and a net margin of 19.39%.The business’s quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.58 EPS. Illinois Tool Works has set its FY 2026 guidance at 11.350-11.550 EPS. As a group, sell-side analysts expect that Illinois Tool Works Inc. will post 11.45 earnings per share for the current year.

Illinois Tool Works Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, October 9th. Shareholders of record on Wednesday, September 30th will be given a $1.72 dividend. This is a positive change from Illinois Tool Works’s previous quarterly dividend of $1.61. The ex-dividend date is Wednesday, September 30th. This represents a $6.88 annualized dividend and a yield of 2.4%. Illinois Tool Works’s payout ratio is currently 58.39%.

Illinois Tool Works Profile (Free Report)

Illinois Tool Works Inc (ITW) is a diversified industrial manufacturer that designs and produces a broad array of engineered products, consumables and related service solutions for industrial customers. Its offerings span engineered fastening systems, specialty components, industrial equipment, welding products, foodservice and packaging equipment, adhesives and polymer products, and test-and-measurement technologies. These products are used as critical inputs by customers across automotive, construction, electronics, foodservice, maintenance and other industrial end markets.

The company operates a decentralized business model in which independently managed businesses focus on niche product lines and close customer relationships.

Featured Stories Five stocks we like better than Illinois Tool Works VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding ITW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illinois Tool Works Inc. (NYSE:ITW – Free Report).

Receive News & Ratings for Illinois Tool Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illinois Tool Works and related companies with MarketBeat.com's FREE daily email newsletter.

Biondo Investment Advisors LLC purchased a new stake in Automatic Data Processing, Inc. (NASDAQ:ADP – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 43,540 shares of the business services provider’s stock, valued at approximately $9,751,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. bought a new position in Automatic Data Processing during the 2nd quarter worth $8,097,229,000. Deutsche Bank AG acquired a new position in shares of Automatic Data Processing during the second quarter valued at approximately $994,937,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Automatic Data Processing by 6,493.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,468,180 shares of the business services provider’s stock valued at $892,120,000 after buying an additional 3,415,576 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Automatic Data Processing during the 2nd quarter valued at about $725,513,000. Finally, Cardano Risk Management B.V. boosted its holdings in Automatic Data Processing by 950.1% during the fourth quarter. Cardano Risk Management B.V. now owns 3,563,180 shares of the business services provider’s stock worth $916,557,000 after buying an additional 3,223,855 shares in the last quarter. Institutional investors own 80.03% of the company’s stock.

Automatic Data Processing Stock Performance Shares of NASDAQ ADP opened at $280.81 on Monday. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.82. The stock has a 50 day moving average of $249.66 and a 200-day moving average of $226.17. Automatic Data Processing, Inc. has a 12 month low of $188.16 and a 12 month high of $308.89. The company has a market capitalization of $111.56 billion, a P/E ratio of 25.67 and a beta of 0.81.

Automatic Data Processing (NASDAQ:ADP – Get Free Report) last posted its earnings results on Wednesday, July 29th. The business services provider reported $2.64 EPS for the quarter, beating the consensus estimate of $2.59 by $0.05. Automatic Data Processing had a return on equity of 71.34% and a net margin of 20.11%.The company had revenue of $5.47 billion for the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter in the prior year, the business earned $2.26 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Automatic Data Processing has set its FY 2027 guidance at 12.120-12.340 EPS. As a group, equities research analysts predict that Automatic Data Processing, Inc. will post 12.26 EPS for the current year. Automatic Data Processing Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, September 11th will be paid a dividend of $1.70 per share. This represents a $6.80 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, September 11th. Automatic Data Processing’s payout ratio is presently 62.16%.

Insiders Place Their Bets In other news, VP David Kwon sold 2,414 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $265.62, for a total value of $641,206.68. Following the completion of the transaction, the vice president owned 9,660 shares of the company’s stock, valued at $2,565,889.20. This represents a 19.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In ADP has been the subject of several research analyst reports. Robert W. Baird reduced their price target on shares of Automatic Data Processing from $300.00 to $270.00 in a research report on Thursday, April 30th. Mizuho reduced their target price on shares of Automatic Data Processing from $332.00 to $305.00 in a research note on Thursday, April 30th. UBS Group increased their price objective on Automatic Data Processing from $260.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, July 22nd. Stifel Nicolaus upped their price target on shares of Automatic Data Processing from $260.00 to $285.00 and gave the company a “hold” rating in a report on Thursday, July 30th. Finally, Guggenheim increased their price objective on Automatic Data Processing from $270.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Automatic Data Processing presently has a consensus rating of “Hold” and a consensus target price of $273.50.

Get Our Latest Research Report on ADP

(Free Report)

Automatic Data Processing, Inc (ADP) is a global provider of cloud-based human capital management (HCM) and payroll solutions. Founded in 1949 and headquartered in Roseland, New Jersey, ADP began as a payroll processing company and has evolved into a diversified provider of workforce management, HR, benefits administration, tax and compliance services, and analytics for employers of all sizes.

ADP’s product portfolio includes payroll processing and tax filing, time and attendance systems, benefits administration, talent management, and HR outsourcing.

Recommended Stories Five stocks we like better than Automatic Data Processing VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding ADP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Automatic Data Processing, Inc. (NASDAQ:ADP – Free Report).

Receive News & Ratings for Automatic Data Processing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Automatic Data Processing and related companies with MarketBeat.com's FREE daily email newsletter.

Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Sysco Corporation (NYSE:SYY – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 246,887 shares of the company’s stock, valued at approximately $20,635,000. Barrow Hanley Mewhinney & Strauss LLC owned about 0.05% of Sysco as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Lloyd Advisory Services LLC. purchased a new stake in shares of Sysco in the 4th quarter worth approximately $25,000. Motiv8 Investments LLC purchased a new position in Sysco during the 4th quarter worth $25,000. Sunbelt Securities Inc. increased its holdings in shares of Sysco by 87.6% during the first quarter. Sunbelt Securities Inc. now owns 364 shares of the company’s stock valued at $26,000 after acquiring an additional 170 shares in the last quarter. Torren Management LLC purchased a new position in shares of Sysco in the fourth quarter worth $27,000. Finally, Bard Associates Inc. acquired a new stake in Sysco during the 4th quarter worth about $27,000. Institutional investors own 83.41% of the company’s stock.

Wall Street Analysts Forecast Growth Several research firms have issued reports on SYY. UBS Group increased their price objective on shares of Sysco from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Melius Research downgraded shares of Sysco from a “hold” rating to a “sell” rating in a research report on Tuesday, July 7th. Sanford C. Bernstein lowered their price objective on Sysco from $90.00 to $85.00 and set a “market perform” rating on the stock in a report on Wednesday, April 29th. Citigroup increased their target price on Sysco from $82.00 to $86.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Piper Sandler boosted their price target on Sysco from $77.00 to $84.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Check Out Our Latest Stock Analysis on SYY Sysco News Roundup Here are the key news stories impacting Sysco this week:

Positive Sentiment: Sysco appointed Jason Murray, a former Amazon supply-chain technology executive, and Tom Ondrof, a former Aramark CFO, to its board effective September 1. Their expertise in artificial intelligence, logistics, foodservice, finance, and mergers could strengthen execution and governance. Sysco Announces Strategic Board Appointments and AI Transformation Initiatives Positive Sentiment: The company reiterated fiscal 2027 targets of 6%–7% revenue growth and 9%–11% adjusted EPS growth, including a planned $100 million AI-enabled cost-savings program. Sysco is also upgrading its technology committee to oversee the broader AI transformation. Sysco Gains After Highlighting Board Changes and AI Initiatives Positive Sentiment: D.E. Shaw reportedly owns more than $1 billion of Sysco stock and supports the AI strategy and pending Jetro Restaurant Depot acquisition. Its expected participation in the transaction’s capital raise signals institutional confidence in Sysco’s long-term plans. D.E. Shaw Owns More Than $1 Billion Stake in Sysco Positive Sentiment: Sysco declared a quarterly dividend of $0.55 per share, payable October 23 to shareholders of record October 2. The maintained payout provides income support and indicates continued confidence in cash generation. Sysco Declares Quarterly Dividend Payment Neutral Sentiment: Persistent food inflation and uncertainty around tariffs remain industry-wide considerations. Higher food costs can lift Sysco’s reported sales, but may pressure restaurant demand, customer margins, and Sysco’s profitability if costs cannot be passed through. Trump’s 90-Day Inflation Band-Aid Negative Sentiment: The Jetro Restaurant Depot acquisition still carries regulatory, financing, integration, and execution risks. Any delays, dilution, or failure to deliver expected synergies could weigh on SYY despite the positive strategic narrative. Insider Buying and Selling at Sysco In other news, Director John M. Hinshaw purchased 13,304 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $75.17 per share, with a total value of $1,000,061.68. Following the purchase, the director directly owned 40,200 shares of the company’s stock, valued at $3,021,834. This represents a 49.46% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Ronald L. Phillips sold 6,285 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $83.94, for a total value of $527,562.90. Following the transaction, the executive vice president directly owned 39,970 shares of the company’s stock, valued at $3,355,081.80. The trade was a 13.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.56% of the company’s stock.

Sysco Stock Performance NYSE:SYY opened at $84.04 on Monday. Sysco Corporation has a fifty-two week low of $68.19 and a fifty-two week high of $91.85. The company has a 50 day moving average price of $82.65 and a 200 day moving average price of $80.63. The stock has a market capitalization of $40.23 billion, a P/E ratio of 22.96, a PEG ratio of 2.87 and a beta of 0.64. The company has a debt-to-equity ratio of 4.62, a quick ratio of 0.77 and a current ratio of 1.28.

Sysco (NYSE:SYY – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.02. The business had revenue of $22.12 billion for the quarter, compared to analysts’ expectations of $21.95 billion. Sysco had a net margin of 2.08% and a return on equity of 95.05%. The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 earnings per share. Sysco has set its FY 2027 guidance at 5.025-5.117 EPS and its Q1 2027 guidance at 1.180-1.200 EPS. Equities research analysts forecast that Sysco Corporation will post 5.12 EPS for the current year.

Sysco Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 23rd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.6%. The ex-dividend date is Friday, October 2nd. Sysco’s dividend payout ratio is presently 60.11%.

About Sysco (Free Report)

Sysco Corporation (NYSE: SYY) is a global foodservice distribution company that supplies a broad range of food and related products to restaurants, healthcare and educational facilities, lodging establishments, and other foodservice customers. Its core business is the procurement, warehousing and delivery of fresh, frozen and dry food products, complemented by non-food items such as paper goods, kitchen equipment, cleaning supplies and tabletop products. Sysco serves customers through an extensive network of distribution centers and dedicated delivery fleets, positioning itself as a one-stop supplier for operators of all sizes.

Founded in 1969 and headquartered in Houston, Texas, Sysco has grown through both organic expansion and acquisitions.

Read More Five stocks we like better than Sysco VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Sysco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysco and related companies with MarketBeat.com's FREE daily email newsletter.

LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing
for initiation and maintenance (approved in the U.S.)

, /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that once weekly lecanemab‑irmb subcutaneous injection (brand name: LEQEMBI IQLIK®) is now available in the U.S. for initiation therapy for early Alzheimer's disease (AD) in adults with mild cognitive impairment (MCI) or mild dementia due to AD, collectively referred to as early AD. MCI due to AD is the earliest symptomatic stage of AD and can appear with subtle symptoms such as forgetfulness, confusion, or feeling at a loss for words.1 

LEQEMBI IQLIK is administered via an autoinjector, introducing a convenient alternative to intravenous (IV) dosing from the start of treatment. For initiation, the approved regimen is 500 mg given once weekly as two consecutive 250 mg injections, each delivered in approximately 15 seconds. LEQEMBI IQLIK may also be used for maintenance dosing at 360 mg once weekly after 18 months of IV or subcutaneous (SC) treatment. Throughout the entire treatment course – from initiation through maintenance – patients may receive LEQEMBI either as IV infusion or as SC injection with LEQEMBI IQLIK. Patients may also switch from IV to SC administration, or vice versa, providing greater convenience and flexibility in LEQEMBI administration.

Expanding Treatment Convenience and Flexibility Across the Alzheimer's Disease Care Pathway
The availability of LEQEMBI IQLIK for both initiation and maintenance therapy in the U.S. enhances treatment convenience and flexibility, offering early AD patients and their care partners more control in managing their care while lowering barriers to initiating and continuing treatment with LEQEMBI. LEQEMBI IQLIK may reduce the time spent receiving anti-amyloid therapy via IV infusions. In addition, at-home administration allows patients and their care partners to continue treatment without the burden of clinic visits, making it easier to go out and travel. LEQEMBI IQLIK also has the potential to reduce healthcare resources associated with IV dosing, such as infusion preparation and nurse monitoring. These features may help streamline the overall AD treatment pathway. For ARIA monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation.

Support Resources for LEQEMBI IQLIK
Eisai and Biogen will provide a range of resources to help patients, care partners, healthcare providers, health systems and pharmacies successfully implement and use LEQEMBI IQLIK.

Patient Support
Resources include an Instructions for Use (IFU) video and IQLIK Welcome Kit. The IQLIK Welcome Kit provides a What to Expect Treatment Tracker, an injection reminder magnet, and a Demo Kit to help patients and care partners understand what to expect, prepare for at-home injections, and administer injections safely at home. The LEQEMBI Companion® app will also be available. It brings the information patients and care partners need into one experience, including education about the injection process and tools for tracking each dose.

Patients initiating IQLIK will be encouraged to bring the Welcome Kit to their initial dosing appointment. Kits will be available through: 

The LEQEMBI Specialty Pharmacy Network (CareMed Specialty Pharmacy and Walgreens Specialty Pharmacy)   Integrated Delivery Networks (IDNs) or the prescribing physician  LEQEMBI Companion® - a program offering financial support information and options for eligible patients.   Through the LEQEMBI Specialty Pharmacy Network, patients may receive support with prescription fulfillment, insurance coverage navigation, onboarding, delivery coordination, device-use education, and – if they choose to participate – treatment reminders and educational support during the first six months of therapy. Patients using other eligible specialty pharmacies may have access to similar support, which may vary by pharmacy.

Healthcare Provider Resources
Electronic Health Record (EHR) support materials and a step-by-step Getting Started Guide will help providers navigate the process from prescription submission through therapy initiation.

Financial Assistance
To further support access to LEQEMBI for certain patients who need help paying for their medicines, Eisai's Patient Assistance Program (PAP) will provide LEQEMBI and LEQEMBI IQLIK at no cost, for eligible uninsured patients, who meet financial need and other program criteria.

*The LEQEMBI Companion app was developed to deliver behavior-driven digital support for patients and care partners along their treatment journey, in partnership with Medisafe Ltd., a behavioral patient engagement engine built for complex and specialty therapies. Patients can visit LEQEMBI.com/CompanionAppSignUp to get started.

Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

INDICATION
LEQEMBI® is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)

•

Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI.

•

Apolipoprotein E ε4 (ApoE ε4) Homozygotes: Patients who are ApoE ε4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA.

•

Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI.

CONTRAINDICATION
Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES
Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.

Incidence of ARIA
Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.

Incidence of ICH
ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.

Risk Factors of ARIA and ICH

ApoE ε4 Carrier Status
Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.

Radiographic Findings of CAA
Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.

The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.

Concomitant Antithrombotic or Thrombolytic Medication
In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.

Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.

Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.

Radiographic Severity With LEQEMBI
Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).

Monitoring and Dose Management Guidelines
Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

HYPERSENSITIVITY REACTIONS

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.

INFUSION-RELATED REACTIONS (IRRs)

IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.

ADVERSE REACTIONS

The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%) The safety profile of subcutaneous LEQEMBI was similar to intravenous infusion. Subcutaneous dosing was associated with mostly localized (erythema, induration, swelling, heat, pain, pruritus, rash, ecchymosis, nodule, and hematoma) and less frequent systemic (headache, chills, fever, and fatigue) injection-related reactions, majority at first dose when initiating therapy. Localized reactions that were recurrent and/or delayed were observed. Severe localized reactions and cases leading to dose discontinuation or interruption occurred. LEQEMBI (lecanemab-irmb) is available:

Intravenous infusion: 100 mg/mL Subcutaneous injection: 200 mg/mL Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.

Click here to access the LEQEMBI digital library with assets available for download.

MEDIA CONTACTS

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120 

Biogen Inc.

Madeleine Shin

+1-781-464-3260

[email protected]  

Eisai Europe, Ltd.

EMEA Communications Department

+44 (0) 7760 619251

[email protected]

Eisai Inc. (U.S.)

Julie Edelman

+1-862-213-5915

[email protected] 

INVESTOR CONTACTS

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

Biogen Inc.

Tim Power

+ 1-781-464-2442

[email protected]

Notes to Editors

About lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the U.S., China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks is approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was obtained in the United States in July 2026, and applications are under review in four countries, including Japan and China. In China, the application has been granted Priority Review designation. Since December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List," recently introduced by the National Healthcare Security Administration (NHSA) of China.

LEQEMBI's approvals in these countries were based on Phase 3 data from Eisai's global placebo-controlled, double-blind, parallel-group, randomized Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). Clarity AD evaluated lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer's disease, which involved 1,795 patients (treatment group: 898, placebo group: 897). 95% of patients who completed the core study (18 months) chose to continue in the long-term extension study (LTE), with 478 patients still receiving treatment for four years. In the Clarity AD core clinical study, data showed LEQEMBI IV significantly slowed disease progression at 18 months (27% vs placebo), and the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale.

To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person's ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.

LEQEMBI also rapidly reduced plaque as early as three months (−59.1 CL difference vs placebo in amyloid level at 18 months; P<0.00001).* Additionally, LEQEMBI continued to show benefit over a four-year LTE treatment period; in a subgroup analysis, 81 percent of LEQEMBI patients who stayed on treatment remained in the early AD stages at four years.**

Over three years of treatment, including both the core study and the LTE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI)** cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four-year mark. In Clarity AD, the most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.

*The Centiloid scale is used for amyloid PET, where 0 CL is anchored as the average amyloid in young people without amyloid plaques, and 100 is anchored as the average amyloid level in moderate AD.  The baseline centiloid level in CLARITY AD was approximately 78 CL. Plaque negativity is defined as conversion to amyloid PET negative (<30 centiloid, or CL).

**Prespecified subgroup analysis of reduced risk of progression: Progression was defined as CDR-SB score progressing to moderate or severe dementia (≥9.5), based on Kaplan-Meier plots.

About Protofibrils
Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.2 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.3 About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned "Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References

National Institute on Aging (NIA), National Institutes of Health. What Is Mild Cognitive Impairment? Available at: https://www.nia.nih.gov/health/memory-loss-and-forgetfulness/what-mild-cognitive-impairment. Accessed July 22, 2026. Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z. Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706. SOURCE Eisai Inc.

ToplineCalifornia Attorney General Rob Bonta accused Paramount’s leadership of leaking information and acting in bad faith as he canceled a planned meeting with the media giant’s executives scheduled for Monday to discuss a potential settlement in an antitrust suit to block Paramount’s acquisition of Warner Bros. Discovery.

The California Attorney General accused Paramount's leadership of "demonstrating a lack of good faith."

Getty Images

Key FactsIn a statement shared with Deadline and the New York Times early on Monday, Bonta said Paramount leaked “alleged substance of settlement discussions.”

The California AG accused the media conglomerate of misrepresenting their discussions in these leaks and also “demonstrating a lack of good faith.”

Bonta’s statement, however, left the door open for future talks, saying his office is happy to meet the company’s executives as soon as “Paramount stops playing games and engages sincerely.”

Paramount has not publicly commented on the California attorney general’s remarks.

Monday’s talks were not expected to bring about an immediate resolution in the case brought by several state Democratic attorneys general, but they were set to take place on the backdrop of California Gov. Gavin Newsom saying he would prefer a settlement amid Paramount’s threats to leave California.

tangentAlthough Bonta’s statement didn’t specify what leaks he was talking about, the Wall Street Journal reported on Sunday night Bonta was expected to ask Paramount to divest some cable networks and make a commitment to keeping its movie studio separate from Warner Bros. as part of the settlement. Citing an unnamed source, the Journal reported that lawyers from the company and the AG’s office met last week to discuss the agenda for Monday’s meeting. The report noted Paramount is unlikely to agree to either selling off its cash generating cable channels or keeping Warner Bros.’ studio business separate. An industry source cited by Deadline in an earlier report said the issue has turned into a game of “PR chicken” with Paramount CEO David Ellison believing the company could force Bonta to back off “with threats and intimidation,” mainly the threat to leave California. The report noted that the states suing to block the merger have raised doubts about the feasibility of one of Ellison’s promises, of releasing 30 theatrical films every year.

What Have California officials Said About The Case?At a press conference last week, California Gov. Gavin Newsom said he would prefer a settlement be reached in the multi-state lawsuit opposing Paramount’s acquisition of Warner Bros. “if it’s a good deal.” Newsom said the matter has to be “worked through” and added he was “concerned about the state, our reputation.” Newsom’s remarks come amid Paramount’s threat to leave the state, and the Democratic governor—who is considered one of the front runners for the Democratic Party’s presidential nomination in 2028—said he is taking the threat seriously. “I hope that doesn’t happen, and I’m of the belief that they don’t want to see that happen,” acknowledging such a departure could have a major impact on Hollywood. Xavier Beccera, the Democratic candidate for this year’s California gubernatorial election and former California AG, also said he would prefer a settlement. “I hope it settles before court. It is easier to stand in a conference room and settle than it is to stand in a courtroom,” Beccera said during a Politico event earlier this month. Los Angeles Mayor Karen Bass has also come out in favor of a settlement.

key backgroundParamount’s $110 billion deal to acquire Warner Bros. Discovery hit a major bump last month after a group of 12 states, including California, sued to block the merger. While announcing the suit, Bonta said the deal would result in “higher prices, lower quality, and less content for film and television.” Later in July, a federal judge temporarily paused the merger from going through, saying the states had raised “serious questions” about the deal’s impact. The ruling was a costly blow for the Ellison-led company, which is liable to pay a ticking fee of around $7 million per day or $650 million per quarter if the deal doesn’t close by the end of September. A few days later, Paramount said it had agreed to push back the merger to June 2027 or until five days after the judge makes a decision on the states’ case.

further readingDavid Ellison Says Paramount-Warner Bros. Discovery Scrutiny Is About ‘Whether I Can Be Trusted’ With CNN (Forbes)

Paramount Suffers Major Early Blow In Merger Lawsuit—And Billion-Dollar Losses Could Lie Ahead (Forbes)

Barrow Hanley Mewhinney & Strauss LLC bought a new stake in Jefferies Financial Group Inc. (NYSE:JEF – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 2,545,859 shares of the financial services provider’s stock, valued at approximately $127,242,000. Barrow Hanley Mewhinney & Strauss LLC owned 1.31% of Jefferies Financial Group as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JEF. BlackRock Inc. acquired a new position in Jefferies Financial Group in the second quarter valued at about $834,947,000. Alyeska Investment Group L.P. raised its position in Jefferies Financial Group by 422.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 3,972,352 shares of the financial services provider’s stock valued at $246,167,000 after purchasing an additional 3,211,375 shares in the last quarter. Eminence Capital LP raised its holdings in shares of Jefferies Financial Group by 13.5% in the 4th quarter. Eminence Capital LP now owns 3,812,615 shares of the financial services provider’s stock valued at $236,268,000 after purchasing an additional 454,054 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Jefferies Financial Group by 696.8% in the 4th quarter. AQR Capital Management LLC now owns 3,412,301 shares of the financial services provider’s stock valued at $211,460,000 after acquiring an additional 2,984,055 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Jefferies Financial Group by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 2,942,554 shares of the financial services provider’s stock valued at $182,390,000 after acquiring an additional 24,171 shares during the last quarter. 60.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In Several analysts have commented on the company. Oppenheimer decreased their price objective on Jefferies Financial Group from $87.00 to $83.00 and set an “outperform” rating for the company in a research report on Thursday, June 25th. Morgan Stanley increased their price target on shares of Jefferies Financial Group from $44.00 to $50.00 and gave the company an “equal weight” rating in a report on Tuesday, June 9th. Weiss Ratings raised shares of Jefferies Financial Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, August 12th. Loop Capital set a $60.00 target price on shares of Jefferies Financial Group in a report on Monday, June 8th. Finally, UBS Group reduced their price target on shares of Jefferies Financial Group from $67.00 to $65.00 and set a “neutral” rating for the company in a research report on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $62.62.

Read Our Latest Analysis on JEF Jefferies Financial Group Stock Up 0.0% JEF stock opened at $52.35 on Monday. The company has a debt-to-equity ratio of 1.99, a current ratio of 0.98 and a quick ratio of 0.98. The company’s 50 day simple moving average is $55.34 and its 200-day simple moving average is $50.93. Jefferies Financial Group Inc. has a 12 month low of $35.53 and a 12 month high of $71.04. The firm has a market capitalization of $10.14 billion, a PE ratio of 14.62 and a beta of 1.54.

Jefferies Financial Group (NYSE:JEF – Get Free Report) last issued its quarterly earnings data on Wednesday, June 24th. The financial services provider reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.14). The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.30 billion. Jefferies Financial Group had a return on equity of 9.23% and a net margin of 7.58%.The company’s revenue for the quarter was up 35.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Equities analysts expect that Jefferies Financial Group Inc. will post 3.71 earnings per share for the current fiscal year.

Jefferies Financial Group announced that its board has approved a share repurchase program on Wednesday, June 24th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the financial services provider to buy up to 2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Jefferies Financial Group Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Tuesday, August 18th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Tuesday, August 18th. Jefferies Financial Group’s dividend payout ratio is currently 44.69%.

(Free Report)

Jefferies Financial Group Inc is a diversified financial services company that provides a range of investment banking, capital markets and asset management services to corporations, governments and institutional investors worldwide. Through its core platform, Jefferies offers advisory services for mergers and acquisitions, debt and equity underwriting, restructuring and recapitalization. The firm also operates a global sales and trading business covering equities, fixed income and foreign exchange products, complemented by equity research and macroeconomic analysis.

In addition to its capital markets franchise, Jefferies maintains a growing asset management division that delivers customized investment solutions across public and private markets.

Recommended Stories Five stocks we like better than Jefferies Financial Group VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Jefferies Financial Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jefferies Financial Group and related companies with MarketBeat.com's FREE daily email newsletter.

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Wrap Technologies, Inc. (Nasdaq: WRAP) (“WRAP” or the “Company”), a global public safety technology company delivering intelligent detection, orchestration and response solutions designed for the next generation of human-centered public safety, today announced the expansion of its strategic relationship with Frenel Imaging Ltd. (“Frenel”) into a broader commercial framework through which advanced technologies sourced by Frenel can be brought into WRAP’s WrapShield™ platform and commercialized across United States and NATO markets.

The first capability being advanced under that framework is laser directed energy for counter unmanned aircraft systems (C-UAS), in which Frenel’s passive thermal polarimetric detection and classification technology is being integrated as the perception and tracking layer for laser effector systems developed by an established directed-energy manufacturer.

The announcement comes five days after WRAP disclosed a $12.0 million institutional financing. The Company now looks to expand WrapShield across a larger public safety, defense and enterprise market. This is the first capability advanced under that initiative.

Laser Directed Energy: Mobile, Scalable and Built for Repeated Engagement

The directed-energy technology being advanced through the Frenel relationship includes a family of fiber-laser counter-UAS capabilities designed to address different operational environments.

Approximately 3 kW man-portable configuration designed for a smaller, deployable counter-UAS footprint.Approximately 6 kW mobile vehicle or pickup-mounted configuration designed to move with the mission and provide counter-UAS protection across changing operating areas.Approximately 9–12 kW stationary or fixed-site configuration designed for protection of installations, infrastructure and other persistent operating locations.Integrated gimbal and fire-control subsystems supporting precision pointing, tracking and controlled target engagement.Dazzler capability as part of the associated directed-energy product architecture.Speed-of-light energy delivery once a target has been detected, tracked and positively authorized for engagement.Rapid repeated-engagement capability, reducing dependence on a finite inventory of traditional kinetic interceptors.Magazine depth primarily constrained by available power rather than interceptor inventory, creating fundamentally different economics for sustained counter-UAS operations.Mobile employment, allowing directed-energy response to move with operational requirements rather than remaining limited to permanent defensive positions.Integration with external sensing, tracking and command-and-control, allowing the laser to operate as an effector within a broader coordinated response architecture rather than as a standalone system. The underlying technology documentation identifies approximately 3 kW man-portable, 6 kW vehicle-mounted and 9–12 kW fixed-site fiber-laser systems together with associated dazzler, gimbal and fire-control subsystems.

For WRAP, the mobile configuration is particularly important.

The Company sees an emerging requirement for counter-UAS protection that can move with the mission: supporting forward locations, border sectors, critical infrastructure and specialized tactical operations where the threat can shift faster than permanent defensive infrastructure can be deployed.

WrapShield Has Been Compounding in Public

WRAP’s recent expansion has been guided by a single operating principle: Lowest Reasonable Response™ - applying the least amount of force reasonably capable of resolving a situation, as early as possible and under human authority. Over the past several weeks, the Company has systematically expanded the WrapShield™ architecture across technology, training, private security, public safety, and new markets, building a coordinated platform designed to detect earlier, respond more proportionately, and create greater accountability across every layer of the response.

July 15 — Expanded Non-Lethal Response: Introduced the Wraptor MX™ multi-shot platform, expanding WrapShield’s non-lethal response layer to three coordinated delivery mechanisms.July 30 — Expanded into Private Security: Extended WrapReality™ into the private security market through a deployment with Stark Security.August 7 — Launched WrapTactics™: Completed the training foundation of WrapShield with the enterprise launch of WrapTactics™, an LMS designed to make training, policy, and operational readiness accountable and auditable across the architecture.August 11 — 103% Year-Over-Year Q2 Revenue Growth: Reported second-quarter financial results reflecting 103% year-over-year revenue growth, alongside the ATF determination that the BolaWrap® 150 is neither a firearm nor a weapon.August 13 — Launched Safe Response with XINSURANCE: Expanded into the approximately 1.28 million-person U.S. private security workforce through a certified Safe Response standard combining technology, training, and insurance alignment.August 14 — Selected for Florida Teacher Safety Initiative: Selected to support a state-funded teacher safety initiative in Florida, further extending WRAP’s training capabilities into community safety and preparedness.August 19 — Secured $12.0 Million in Growth Capital: Announced a $12.0 million institutional financing. The Economics of Drone Defense Have Inverted

Low-cost drones are changing the economics of defense. Inexpensive, increasingly autonomous aircraft can force defenders to expend costly, finite interceptors, while emerging platforms can operate without traditional RF links. Directed energy changes this equation by replacing expensive interceptor inventory with energy, creating the potential for dramatically lower cost per engagement and greater magazine depth.

The Drone Threat Is Moving Beyond the Battlefield

Drone threats are rapidly migrating from military environments into borders, critical infrastructure, correctional facilities, major events, and public safety. As counter-UAS authority expands beyond traditional federal and military users, WRAP believes a significant new market is emerging for technology that can bring proven detection and response capabilities into state, local, and specialized law enforcement environments.

Price Point Determines Market Scale

Counter-UAS capability has historically been priced around the customers able to afford it. Major military installations and combatant commands can support multimillion-dollar fixed-site systems, expensive interceptors, and the infrastructure required to operate them. But the emerging threat is distributed across a much larger global footprint, including forward operating locations, temporary bases, borders, ports, allied military installations, critical infrastructure, and public safety environments. Many of these customers, particularly smaller U.S. agencies, allied and partner nations, and forces operating across multiple dispersed locations, cannot economically deploy traditional counter-UAS infrastructure everywhere it may be needed. The opportunity is therefore not simply to build another high-end counter-UAS system. It is to drive down the acquisition, deployment, and operating costs sufficiently to make effective protection scalable across a much larger domestic and international market.

Directed energy has the potential to change those economics at both the military and public safety levels. A system whose magazine depth is constrained principally by available power rather than expensive interceptor inventory can reduce cost per engagement, support repeated training, and remain operational through sustained or simultaneous attacks. When combined with lighter, mobile configurations that can move with military units, protect temporary or expeditionary locations, integrate onto ground robotic platforms, or be deployed by state and local agencies, the addressable market expands considerably. WRAP believes the winning counter-UAS architecture will not be defined by performance alone. It will be defined by the combination of performance, mobility, affordability, interoperability, and an operating cost that allows U.S. forces, allied nations, and public safety agencies to buy it, train with it, deploy it at scale, and actually use it when needed.

Beyond Counter-UAS: A New Tool for Tactical Law Enforcement

WRAP believes the approximately 3 kW portable architecture may also create a new category of directed-energy capability for specialized law-enforcement and SWAT operations. The Company intends to evaluate applications including standoff breaching, lock and barrier removal, and other controlled-access requirements where increasing the distance between an operator and a physical hazard may improve tactical options.

The same portable architecture may also be appropriate for integration onto ground robotic systems, allowing directed energy to be remotely positioned or delivered into environments where sending an officer, agent or service member may create unnecessary exposure.

For WRAP, this illustrates the larger WrapShield opportunity: a technology sourced for one demanding mission can become a common capability across defense, homeland security, tactical law enforcement and unmanned systems.

Extending the WrapShield™ Response Layer

WrapShield is WRAP’s integrated public safety and defense architecture, organized around three layers across 6 tiers. ‘Detect’ provides passive sensing and early identification, including Frenel’s polarimetric imaging and edge processing. ‘Orchestrate’ provides command, coordination and human-supervised decision making. ‘Respond’ provides an expanding family of response capabilities selected according to the threat, the environment, the mission and the applicable authority.

Until now the response layer has addressed threats at human scale and human range, spanning handheld restraint, multi-shot delivery through Wraptor MX and remotely delivered response through unmanned platforms. Directed energy extends that layer into a different threat class entirely and introduces the first non-kinetic effector in the architecture. The tiered logic does not change. It simply now reaches the air.

Operationally the full chain runs as follows:

Detect, classify, track, prioritize, hand off, authorize, engage, assess.

The laser therefore functions as one response option inside a coordinated architecture operating under positive human control, rather than as a standalone weapon. Authorization remains a human decision at every tier, which is the same principle that governs every other capability WRAP fields.

Directed energy is not the correct answer in every environment, and WRAP does not present it as one. Energy based defeat is best suited to installations, border sectors, critical infrastructure and controlled operating areas where standoff and clear engagement geometry can be established. In dense, populated settings the calculus changes, and considerations including falling debris and collateral risk become decisive. That is precisely why the architecture is tiered to provide the flexibility to switch between “soft” and “hard” energy-based interception, and why authorization always remains with a human being. The value of a coordinated response layer is not that it offers a single answer, rather the fact that it offers the appropriate one and can tell an operator which is which.

Frenel as a Technology Pipeline Into WrapShield™

The larger strategic opportunity for WRAP is not limited to directed energy.

Under the expanded framework, qualifying technologies for which Frenel obtains the necessary rights can be introduced into the WRAP relationship for potential inclusion within WrapShield and commercialization through WRAP’s established channels. The structure is designed to create a repeatable technology pipeline rather than a one-time licensing transaction.

WRAP intends to use that pipeline to identify advanced capabilities developed against demanding operational requirements, including technologies developed and matured against real security and battlefield requirements, and to perform the work required to turn them into programs that United States and NATO customers can actually buy. That work includes systems integration, software and command-and-control interfaces, engineering adaptation, productization, United States sourcing and manufacturing where appropriate, cybersecurity, export control compliance, federal procurement readiness, testing, certification, training and sustainment.

It is deliberately unglamorous work, and it is the reason the model is difficult to replicate. Advanced technology developed elsewhere rarely fails on merit in the United States market. It fails on qualification, compliance, supply chain control and the absence of a party willing to carry it through federal procurement. WRAP is aiming to build itself to be that party.

Executive Commentary

“The math of drone defense is upside down. An adversary can field increasingly capable drones at a fraction of what it costs to defeat them with traditional interceptors,” said Jared Novick, President and Chief Operating Officer of WRAP. “Directed energy flips that equation, but only if you can aim it. A laser has to hold a beam on a small moving object long enough to do the work, and that makes the sensing layer the hardest part of the problem rather than the easiest. What we hold through Frenel is precisely the layer that makes a low-cost effector usable in the conditions where these engagements actually happen. And cost is not an abstraction here. A department will not authorize a response that costs more to use than its annual training budget. Getting both numbers down—the cost of the system and the cost of the shot—is what determines whether this capability remains concentrated at major installations or can scale across borders, forward locations, allied forces and public safety.”

“WRAP and Frenel began with a differentiated sensing technology, and the opportunity was always larger than that,” said Scot Cohen, Chairman and Chief Executive Officer of WRAP. “Our expanded framework creates a path to bring additional advanced technologies into the relationship where we have the rights to do so, with WRAP providing the integration and commercialization capability around what United States and NATO customers actually require. Directed energy is a powerful demonstration of that model, because it takes WrapShield from seeing a threat earlier to coordinating an effective response against a class of threat we could not previously reach.”

The WrapShield™ Thesis

WRAP believes the convergence of public safety, homeland security, defense, border security, critical infrastructure and autonomous systems is creating a new technology market, and that the defining position in that market will not belong to the best individual sensor or the cheapest individual effector. It will belong to whoever owns the layer where perception and response have to agree.

The Company’s strategy is to build WrapShield as the integration and commercialization architecture across that convergence, combining differentiated sensing, intelligence, command and control, and response technologies around specific customer and mission requirements. The model is demanding to execute:

Identify differentiated technologies capable of solving operational problems that current tools do not solve.Integrate them into a coordinated Detect, Orchestrate and Respond architecture rather than selling them as separate components.Invest selectively where United States adaptation, qualification, sourcing, manufacturing or support creates strategic or commercial value.Build resilient United States supply and support infrastructure where the mission or the customer requires it.Support United States federal customers including the Department of War and the Department of Homeland Security against rapidly evolving threats.Commercialize globally through the markets, partners and channels best suited to each opportunity.Accelerate advanced technologies to the operators who need them most through vertical integration, cost discipline and a training-first foundation. WRAP does not intend to relocate technology or manufacturing to the United States for its own sake. The Company intends to build United States controlled technology, supply chain and support capability where doing so creates strategic value, including where required to serve federal customers, to satisfy security, procurement or restricted value chain requirements, to improve supply chain resilience, to provide domestic sustainment and lifecycle support, or to address the scale of the United States market.

Frenel expands the technology pipeline and R&D resources. WRAP determines where to invest and then streamlines and integrates the capabilities through WrapShield. Where the mission requires it, WRAP intends to build the American infrastructure necessary to support the American customer.

About Wrap Technologies, Inc.

Wrap Technologies, Inc. (Nasdaq: WRAP) is a global public safety technology company delivering intelligent detection, orchestration and response solutions designed for the next generation of intelligent, human-centered public safety. The Company’s WrapShield™ platform unifies detection, orchestration and response into an integrated, human-supervised architecture spanning law enforcement, homeland security, defense, enterprise and critical infrastructure customers. Powered by the BolaWrap® 150, Wraptor MX™, WRAP Reality™, the WrapTactics™ learning management system and Frenel TPiCore® polarimetric sensing, WRAP builds on the principle that technology and trained human judgment must advance together. For Humans, By Humans. WRAP is headquartered in Miami, Florida. For more information visit www.wrap.com.

About Frenel Imaging Ltd.

Frenel Imaging Ltd. develops and licenses the TPiCore® polarimetric image signal processing framework and associated polarimetric thermal, near-infrared and daylight sensors, providing passive day-and-night detection, classification and discrimination of unmanned aircraft and other targets, including against cluttered and below-skyline backgrounds and without radio-frequency emission.

Forward Looking Statements

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expanded framework with Frenel Imaging Ltd., the development, integration, qualification and commercialization of directed-energy counter-UAS capability, the anticipated use of proceeds from the Company’s recent financing, the expansion of the WrapShield platform and its response layer, potential tactical law-enforcement, standoff breaching, lock or barrier removal and ground-robotic applications, potential future technologies and partnerships, addressable markets, and the Company’s strategic direction. The integration described in this release is in a development phase, has not completed demonstration or qualification, and no assurance can be given that it will be completed on the anticipated timeline or at all. Definitive agreements relating to the underlying collaboration have not been executed and there is no obligation on any party to enter into them. Statements are based on current expectations and assumptions subject to risks and uncertainties, including the pace of customer and agency adoption, the timing and outcome of federal procurement and export control processes, the availability and terms of technology partnerships, regulatory developments, competitive conditions, and the Company’s ability to attract and retain personnel. Actual results could differ materially from those expressed or implied. WRAP undertakes no obligation to update or revise any forward looking statement, and investors are cautioned not to place undue reliance on them.

Investor Relations Contact:
(800) 583-2652
[email protected]
Wrap.com

Bank of New York Mellon Corp purchased a new stake in shares of International Flavors & Fragrances Inc. (NYSE:IFF – Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,550,018 shares of the specialty chemicals company’s stock, valued at approximately $122,792,000. Bank of New York Mellon Corp owned approximately 0.61% of International Flavors & Fragrances at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Tema ETFs LLC increased its holdings in shares of International Flavors & Fragrances by 9.4% in the second quarter. Tema ETFs LLC now owns 5,078 shares of the specialty chemicals company’s stock valued at $402,000 after purchasing an additional 435 shares during the period. Peoples Bank KS increased its holdings in International Flavors & Fragrances by 5.1% in the 2nd quarter. Peoples Bank KS now owns 4,686 shares of the specialty chemicals company’s stock worth $371,000 after buying an additional 228 shares during the period. Contravisory Investment Management Inc. purchased a new position in International Flavors & Fragrances during the 2nd quarter worth approximately $1,112,000. HF Advisory Group LLC raised its position in International Flavors & Fragrances by 1.3% during the 2nd quarter. HF Advisory Group LLC now owns 17,847 shares of the specialty chemicals company’s stock worth $1,414,000 after buying an additional 233 shares during the last quarter. Finally, Everhart Financial Group Inc. acquired a new stake in International Flavors & Fragrances during the 2nd quarter valued at approximately $208,000. 96.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets Several research analysts recently issued reports on IFF shares. Morgan Stanley raised their target price on shares of International Flavors & Fragrances from $93.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, July 1st. BNP Paribas Exane upped their price target on shares of International Flavors & Fragrances from $85.00 to $95.00 in a report on Thursday, May 7th. Rothschild & Co Redburn cut their price target on International Flavors & Fragrances from $74.00 to $71.00 in a research report on Friday, May 8th. Benchmark lifted their price objective on International Flavors & Fragrances from $100.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on International Flavors & Fragrances from $95.00 to $90.00 and set a “buy” rating for the company in a report on Monday, June 1st. Thirteen analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $92.16.

View Our Latest Stock Report on International Flavors & Fragrances Insider Transactions at International Flavors & Fragrances In related news, EVP Michael Deveau sold 8,825 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $85.55, for a total value of $754,978.75. Following the completion of the transaction, the executive vice president directly owned 5,199 shares of the company’s stock, valued at approximately $444,774.45. This represents a 62.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider De Mendonca Ana Paula Teles sold 5,718 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $83.19, for a total value of $475,680.42. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,543 shares of company stock valued at $1,315,659 in the last 90 days. Corporate insiders own 1.07% of the company’s stock.

Trending Headlines about International Flavors & Fragrances Here are the key news stories impacting International Flavors & Fragrances this week:

Positive Sentiment: IFF is trading above its 50-day and 200-day moving averages and near its 52-week high, signaling continued investor momentum even though the latest reports do not identify a new fundamental catalyst. Positive Sentiment: The company authorized a $2.5 billion share-repurchase program, potentially covering up to 12.1% of outstanding shares. The buyback may support earnings per share and suggests management believes the stock is undervalued. Positive Sentiment: Institutional ownership remains high at approximately 96%, while several large investors—including BlackRock, Invesco and Ameriprise—recently increased or initiated positions. IFF also declared a quarterly dividend of $0.40 per share. Neutral Sentiment: CEO Erik Fyrwald is scheduled to participate in a Barclays Global Consumer Conference fireside chat on September 10. Investors may look for updates on strategy, operating performance and capital allocation, but no new guidance has been provided. IFF Barclays conference announcement Negative Sentiment: Zacks Research repeatedly lowered its EPS forecasts and maintained a “Strong Sell” rating. FY2026 EPS was cut to $3.14 from $4.45, FY2027 to $3.71 from $4.81, and FY2028 to $4.31 from $5.21. The revisions indicate expectations for weaker profitability over multiple years. Negative Sentiment: The largest near-term reduction was for Q3 2026 EPS, lowered to $0.67 from $1.14. Estimates for Q4 2026 and each quarter of 2027 were also reduced, raising concerns about sustained earnings pressure and IFF’s elevated valuation. Negative Sentiment: An insider sold 5,718 shares for approximately $476,000 at an average price of $83.19. One transaction is not conclusive, but it provides a modest negative signal for investors monitoring insider confidence. IFF insider sale report Negative Sentiment: IFF’s latest reported quarter missed analyst expectations, with EPS of $0.82 versus $1.07 expected and revenue of $1.95 billion versus $2.62 billion expected, reinforcing concerns behind the estimate cuts. International Flavors & Fragrances Price Performance International Flavors & Fragrances stock opened at $84.31 on Monday. The stock has a market capitalization of $21.51 billion, a P/E ratio of 77.35, a P/E/G ratio of 3.12 and a beta of 0.93. The company’s fifty day moving average price is $79.56 and its 200 day moving average price is $76.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.72 and a current ratio of 2.06. International Flavors & Fragrances Inc. has a 1 year low of $59.14 and a 1 year high of $89.32.

International Flavors & Fragrances (NYSE:IFF – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.25). International Flavors & Fragrances had a net margin of 2.78% and a return on equity of 7.11%. The company had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $2.62 billion. During the same period in the previous year, the business earned $1.15 earnings per share. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. As a group, equities research analysts anticipate that International Flavors & Fragrances Inc. will post 3.08 earnings per share for the current fiscal year.

International Flavors & Fragrances Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 9th. Shareholders of record on Friday, September 18th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 1.9%. The ex-dividend date is Friday, September 18th. International Flavors & Fragrances’s payout ratio is 146.79%.

International Flavors & Fragrances declared that its board has authorized a stock buyback program on Tuesday, August 4th that allows the company to repurchase $2.50 billion in outstanding shares. This repurchase authorization allows the specialty chemicals company to repurchase up to 12.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

International Flavors & Fragrances Company Profile (Free Report)

International Flavors & Fragrances Inc (NYSE:IFF) is a global leader in the creation and production of flavors, fragrances, cosmetic actives and nutritional lipids. The company develops taste and scent solutions for a wide array of end markets including food and beverage, personal care, household goods and pharmaceutical products. Its portfolio spans natural and nature-identical flavors, fine fragrances, functional ingredients for skin and hair care, and specialty oils that enhance nutritional value and sensory appeal.

IFF’s research and development network comprises innovation centers in North America, Europe, Asia-Pacific and Latin America, where multidisciplinary teams collaborate on aroma chemistry, sensory science and biotechnology.

Featured Articles Five stocks we like better than International Flavors & Fragrances VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding IFF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for International Flavors & Fragrances Inc. (NYSE:IFF – Free Report).

Receive News & Ratings for International Flavors & Fragrances Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Flavors & Fragrances and related companies with MarketBeat.com's FREE daily email newsletter.

Bank of Nova Scotia acquired a new stake in Stifel Financial Corporation (NYSE:SF – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 519,811 shares of the financial services provider’s stock, valued at approximately $36,267,000. Bank of Nova Scotia owned 0.34% of Stifel Financial at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. bought a new stake in Stifel Financial during the 2nd quarter valued at $1,031,197,000. AQR Capital Management LLC grew its holdings in Stifel Financial by 94.8% during the 4th quarter. AQR Capital Management LLC now owns 2,893,850 shares of the financial services provider’s stock worth $362,368,000 after acquiring an additional 1,408,347 shares in the last quarter. Norges Bank bought a new position in Stifel Financial during the 4th quarter worth about $172,446,000. Bank of New York Mellon Corp purchased a new position in Stifel Financial during the 2nd quarter valued at about $93,235,000. Finally, Algebris UK Ltd. bought a new stake in shares of Stifel Financial in the 2nd quarter valued at about $70,086,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stifel Financial In other news, Director Maryam S. Brown sold 4,700 shares of the stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $79.20, for a total value of $372,240.00. Following the sale, the director owned 5,729 shares in the company, valued at $453,736.80. This represents a 45.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.36% of the stock is owned by company insiders.

Stifel Financial Stock Down 0.0% Shares of SF stock opened at $80.95 on Monday. The stock’s 50-day simple moving average is $78.20 and its 200-day simple moving average is $76.43. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.83 and a current ratio of 0.88. The firm has a market capitalization of $12.22 billion, a PE ratio of 14.49 and a beta of 0.99. Stifel Financial Corporation has a fifty-two week low of $67.81 and a fifty-two week high of $89.83. Stifel Financial (NYSE:SF – Get Free Report) last released its earnings results on Wednesday, July 22nd. The financial services provider reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.09. The firm had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.42 billion. Stifel Financial had a return on equity of 19.22% and a net margin of 16.11%.The company’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 earnings per share. Equities analysts expect that Stifel Financial Corporation will post 6.36 earnings per share for the current year.

Stifel Financial Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, September 1st. Stifel Financial’s dividend payout ratio is 24.33%.

Analyst Ratings Changes A number of equities analysts have recently issued reports on SF shares. UBS Group set a $90.00 price objective on shares of Stifel Financial in a research note on Thursday, July 23rd. Weiss Ratings reissued a “buy (b-)” rating on shares of Stifel Financial in a research note on Friday, May 29th. Wall Street Zen cut Stifel Financial from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. JPMorgan Chase & Co. lifted their price target on Stifel Financial from $80.00 to $86.00 and gave the company a “neutral” rating in a report on Thursday, July 23rd. Finally, Zacks Research raised Stifel Financial from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 20th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.90.

Get Our Latest Stock Analysis on SF

(Free Report)

Stifel Financial Corp. is a diversified financial services holding company headquartered in St. Louis, Missouri. Founded in 1890, the firm has grown into a full‐service brokerage and investment banking organization serving individual investors, corporations and institutions. Through its principal subsidiary, Stifel, Nicolaus & Company, Incorporated, the company delivers a broad array of financial products and services backed by research‐driven insights.

The firm’s main business activities are organized into two core segments: Private Client Group and Institutional Group.

Read More Five stocks we like better than Stifel Financial VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding SF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stifel Financial Corporation (NYSE:SF – Free Report).

Receive News & Ratings for Stifel Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stifel Financial and related companies with MarketBeat.com's FREE daily email newsletter.

Curaleaf's self-serving portrayal of our business is an attempt to acquire Aurora's world class EU-GMP manufacturing facilities and global medical cannabis footprint at the lowest price possible Aurora's international strategy is working; net revenue is up 17%YOY Contrary to Curaleaf's inaccurate statements, Aurora's high margin German business is growing and continues to be a key driver of Aurora's international growth strategy Shareholders are advised to TAKE NO ACTION pending formal recommendation from the Board and Special Committee. Offer remains open for at least 105 days from the launch of the Hostile Bid Questions about the Offer or would like to stay informed? Please contact Kingsdale Advisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or at [email protected] , /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today cautioned shareholders that Curaleaf Holdings, Inc.'s ("Curaleaf") (TSX: CURA) (OTCQX: CURLF) announcement of an unsolicited take-over bid ( "Hostile Bid") appears to contain inaccurate statements about Aurora's business and should be viewed skeptically.

Aurora's Board of Directors, together with a newly formed Special Committee of independent directors, is reviewing Curaleaf's proposal in consultation with financial and legal advisors to determine the course of action that best serves the interests of the Company and its shareholders.

Shareholders are advised to TAKE NO ACTION with respect to the Curaleaf offer at this time.

"Curaleaf's timing and public comments appear to be a transparent attempt to pressure Aurora shareholders into making a short-term decision for the benefit of Curaleaf shareholders," said Miguel Martin, Executive Chairman and CEO of Aurora. "Curaleaf's interest underscores the value that Aurora has created. They are trying to acquire our world-class EU-GMP global infrastructure at the lowest possible price, depriving our shareholders of the long-term value our strategy is built to deliver."

"This opportunistic Hostile Bid comes as Aurora's multi-year transformation into a high-margin, global medical cannabis leader is yielding positive results. With three consecutive years of positive adjusted EBITDA1, accelerating international sales and our recent expansion into the critical UK market, Aurora is reaching a pivotal inflection point," Mr. Martin added.

"The Company's Special Committee of the Board has not yet made a formal recommendation regarding the Offer; Aurora will not let inaccurate statements about the Company stand uncorrected while the review is underway. The Special Committee and Board are focused on protecting shareholder investment and ensuring full value is realized" Mr. Martin concluded.

Setting the record straight

Curaleaf has made several public claims regarding Aurora's operational and market performance that do not accurately or fully reflect the Company's business model or actual financial results:

Response and Engagement to the Offer: As Curaleaf acknowledged in its Hostile Bid circular, Aurora has had several discussions with Curaleaf since June 2026, most recently on August 12. Discussions included Aurora's Lead Independent Director and the Executive Chairman and CEO. Curaleaf's public statements appear to de-emphasize these repeated engagements. International Medical Market Performance: German Market Remains a Major Driver of International Growth: Germany is a key driver of Aurora's 17% year-over-year international net revenue growth in fiscal Q1'27, compared to the prior year quarter, as the Company continues to grow its medical cannabis business in that market. Curaleaf claims that regulatory changes to German medical reimbursement are contributing to a major challenge for Aurora. This is incorrect: the reimbursement market segment accounted for less than 10 percent of Aurora's total German volume prior to these changes. UK Market Position and Growth Opportunities: Aurora is gaining share in the UK, where patients have consistently preferred its high-quality products. On August 19, 2026, Aurora strengthened its position by acquiring Internode Pharma Limited and HAP Pharma Limited, expanding direct distribution in Europe's fastest-growing medical market. Aurora continues to be a market leader in Poland Aurora continues to hold the #1 market share position by revenue in Poland. Increases in annual import limits and a loyal patient base strengthen Aurora's growth outlook in this key, highly-regulated market. Financial Strength Refutes Curaleaf's Claims: Aurora's recent financial performance demonstrates a stronger, more focused business than Curaleaf's characterization suggests. Aurora delivered record global medical cannabis revenue and adjusted EBITDA1 results in FY2026. Momentum continues, with YOY growth in international net revenue and industry leading adjusted gross margins before FV adjustments1 These strong results reflect Aurora's strategy of prioritizing global medical cannabis growth, including exiting the lower-margin Plant Propagation and Canadian Consumer businesses. Curaleaf's Cultivation Claims Ignore the Strength of Aurora's Facilities Curaleaf's comments on Aurora's cultivation methods and output per square foot are inaccurate and outdated, and do not reflect the strength of Aurora's cultivation facilities. Aurora has built specialized expertise in manufacturing facilities that cannot be easily replicated. Through years of operating large-scale EU-GMP-certified facilities, Aurora has developed the scientific, cultivation, regulatory and operational capabilities that support its global medical cannabis strategy. Aurora is proactively expanding capacity to support international growth and ensure consistent supply as regulatory standards tighten and patient demand grows. Over the past five years, Aurora has increased its EU-GMP production capacity by more than 40% and continues to invest further, including through capacity added in the Safari Flower Company transaction. Aurora Shareholders are advised to TAKE NO ACTION with respect to the Curaleaf offer at this time.

Aurora shareholders with questions about the Offer or who would like to stay informed may contact Aurora's strategic advisor and information agent:

Kingsdale Advisors

Toll-Free (within North America): 1-800-749-9052 Call or Text: 416-623-4172 Email: [email protected] ____________________________     

1 Note this press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. These measures are not standardized financial measures under the financial reporting framework used to prepare Aurora's financial statements and might not be comparable to similar financial measures disclosed by other issuers. These terms and the reconciliations to the most comparable GAAP measures are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the FY27 Q1 MD&A, filed August 5, 2026, which can be found on Sedar+, EDGAR and Aurora's website.

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™. 

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements and information about Curaleaf's Hostile Bid, timing and any recommendation with respect to the same, statements regarding the Company's strategy, including expected results with respect to its multi-year transformation into a high-margin, global medical cannabis leader, expectations for accelerating international sales, and continued investment in the Company's EU-GMP platform; and statements regarding the creation of long-term value for shareholders

 These forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion to revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crisis, and other risks as set out under the heading "Risk Factors" in the Company's annual information form dated June 10, 2026 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Non-GAAP Measures1

This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the FY27 Q1 MD&A is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the U.S. Securities and Exchange Commission's (the "SEC") EDGAR website at www.sec.gov.

SOURCE Aurora Cannabis Inc.

For Immediate ReleaseChicago, IL – August 24, 2026 – Today, Zacks Equity Comfort Systems USA (FIX - Free Report) , Carrier Global Corp. (CARR - Free Report) and SPX Technologies, Inc. (SPXC - Free Report)

Industry: HVAC

Link: https://www.zacks.com/commentary/2978143/3-air-conditioner-heating-stocks-to-buy-as-hvac-demand-grows

The Zacks Building Products - Air Conditioner & Heating industry continues to benefit from several favorable trends in 2026. Rapid data center development is driving demand for specialized and energy-efficient cooling systems, while electrification and tighter efficiency standards are supporting heat pumps and other advanced HVAC solutions. Rising adoption of smart controls and connected systems, along with steady service and aftermarket demand, provides further support.

On the downside, weakness in single-family construction and cautious consumer spending continue to limit residential HVAC demand, increasing dependence on replacement activity. Tariffs, commodity and freight inflation also create cost pressures, while investments in new manufacturing capacity can weigh on margins through start-up costs and lower initial utilization. Despite these challenges, companies such as Comfort Systems USA, Carrier Global Corp. and SPX Technologies, Inc. are also expanding their opportunities through acquisitions, digital capabilities and service-oriented business models, while growing demand for indoor air quality and mission-critical cooling supports recurring revenue streams.

Industry DescriptionThe Zacks Building Products - Air Conditioner & Heating industry comprises designers, manufacturers, and marketers of a broad range of products for heating, ventilation, air conditioning, and refrigeration markets. The products include rooftop units, chillers, air-handling units, condensing units and coils. 

The industry players also supply thermostats, insulation materials, refrigerants, grills, registers, sheet metal, tools, concrete pads, tape and adhesives. Air conditioning and heating equipment are sold in residential replacement, commercial and industrial HVAC (heating, ventilation and air conditioning), as well as residential new construction markets.

4 Trends Shaping the Future of the Air Conditioner & Heating IndustryData Center Boom Fuels Commercial HVAC Demand: Rapid investment in AI, cloud computing and hyperscale data centers is emerging as a major growth driver for the U.S. Air Conditioner and Heating industry. These facilities require large, reliable and energy-efficient cooling systems to manage increasingly dense computing workloads. Demand is expanding across air- and water-cooled chillers, custom air handlers, cooling towers, dry and adiabatic cooling systems and related equipment. 

Strong project pipelines are also encouraging manufacturers to expand production capacity and improve throughput. Importantly, hyperscale and colocation projects generally provide greater forward visibility because cooling equipment must be secured well before facilities become operational, supporting a favorable multiyear demand outlook. 

Electrification, Efficiency Upgrades and Smart HVAC Drive Growth: Electrification, tighter efficiency standards and smart-building adoption are supporting U.S. HVAC industry growth in 2026. Demand for electric heat pumps, high-SEER air conditioners and low-GWP refrigerant systems is rising as customers seek lower energy use and compliance with stricter regulations. Federal and state incentives are helping offset upgrade costs, while aging equipment supports resilient replacement demand.

Meanwhile, HVAC systems are becoming more connected through intelligent controls, smart thermostats, humidification systems and actuated valves, improving efficiency, performance and operational visibility. This shift toward higher-value, connected equipment is also expanding service and aftermarket opportunities across residential and commercial markets.

Housing Weakness Limits Residential HVAC Recovery: Residential HVAC demand remains under pressure from persistent weakness in the U.S. housing market. New single-family construction continues to face challenges, while cautious consumer spending is restraining discretionary repair and remodeling activity. A meaningful recovery in residential construction is not expected in 2026, limiting demand for HVAC systems tied to new homes. 

Although earlier channel destocking is fading, underlying demand remains subdued and increasingly reliant on replacement activity rather than new installations. These conditions could keep residential HVAC volumes under pressure and make the segment more vulnerable to housing affordability constraints, elevated borrowing costs and continued consumer caution.

Tariffs, Inflation and Capacity Costs Pressure Margins: Cost pressures remain a key challenge for the U.S. Air Conditioner and Heating industry in 2026. Tariffs are raising costs for certain materials and components, while commodity, freight and other inflationary pressures add uncertainty to the price-cost equation. Pricing actions can offset some of these pressures, but tariff-related price increases do not necessarily translate into higher margins.

At the same time, manufacturers are rapidly expanding capacity to meet strong commercial and data center demand. New facilities and production lines can initially generate start-up costs, lower utilization and operating inefficiencies. Higher utilization, sourcing improvements and productivity gains will therefore be important for margin improvement.

Zacks Industry Rank Indicates Bright ProspectsThe Zacks Building Products - Air Conditioner & Heating industry is a nine-stock group within the broader Zacks Construction sector. The industry currently carries a Zacks Industry Rank #32, which places it in the top 13% of more than 250 Zacks industries. 

The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates optimistic near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

The industry’s positioning in the top 50% of the Zacks-ranked industries is a result of a higher earnings outlook for the constituent companies in aggregate. Looking at the aggregate earnings estimate revisions, it appears that analysts are gradually gaining confidence in this group’s earnings growth potential. Since June 2026, the industry’s earnings estimates for 2026 and 2027 have increased to $5.11 per share (from $4.91) and $5.95 per share (from $5.70), respectively.

We highlight a few stocks that investors may consider adding to their portfolios. First, we examine the industry’s shareholder returns and current valuation backdrop.

Industry Outperforms Sector, Lags S&P 500The Zacks Air Conditioner & Heating industry has outperformed the broader Zacks Construction sector but lagged the Zacks S&P 500 Composite over the past year.

In the same time frame, the industry has gained 16.7% compared with the broader sector’s 6.5% rise. Meanwhile, the Zacks S&P 500 Composite has gained 23.4% during the period.

Industry's Current ValuationOn the basis of the forward 12-month price to earnings, which is a commonly used multiple for valuing Air Conditioner and Heating stocks, the industry is currently trading at 23.87X compared with the S&P 500’s 20.55X and the sector’s 19.99X.

Over the past five years, the industry has traded as high as 30.77X, as low as 15.87X and at a median of 23.97X.

3 Air Conditioner and Heating Stocks to Buy NowBelow, we have discussed three stocks from the Zacks Air Conditioner & Heating universe with solid growth potential.

Comfort Systems: Based in Houston, TX, the company is a national provider of comprehensive heating, ventilation and air conditioning installation, along with maintenance, repair and replacement services. Comfort Systems is benefiting from strong demand across technology and other industrial markets, supported by continued data center construction and rising needs for complex mechanical and electrical infrastructure. Direct relationships with hyperscalers provide visibility into future projects, while sustained customer demand supports further expansion of its modular operations.  

The company is also broadening its modular customer base through opportunities with frontier labs and colocation providers.  Strong institutional demand, disciplined project selection and skilled tradespeople further support execution. Meanwhile, the growing installed base of data centers creates a longer-term opportunity to expand recurring service and maintenance work.

 Comfort Systems currently carries a Zacks Rank #1 (Strong Buy). The stock has gained 142.6% over the past year. FIX has seen an upward estimate revision for 2026 earnings per share (EPS) to $45.86 from $43.05 over the past 30 days. The estimated figure indicates 58.8% year-over-year growth in 2026. Comfort Systems surpassed earnings estimates in all the trailing four quarters, with the average surprise being 34.6%. Again, Comfort Systems’ trailing 12-month return on equity of 53.6% is better than its peer group average of 16.9%. It has a VGM Score of B. You can see the complete list of today’s Zacks #1 Rank stocks here.

SPX Technologies: Headquartered in Charlotte, NC, SPX Technologies supplies infrastructure equipment for global HVAC and detection and measurement markets. SPX Technologies is benefiting from robust demand for data center cooling solutions, supported by hyperscaler, colocation and neocloud customers. Capacity expansions, improved production flow, lean initiatives and higher throughput are strengthening its ability to meet this demand.  

The Neptronic acquisition adds another growth avenue by broadening SPX’s HVAC portfolio with intelligent controls, electric heating, humidification and actuated valves, while expanding its addressable markets.  Strong customer relationships and global distribution channels provide cross-selling opportunities. Meanwhile, healthy project activity, innovation and synergy initiatives in Detection & Measurement, along with an active acquisition pipeline, should support further growth.

SPX Technologies currently carries a Zacks Rank #2. The stock has gained 7.4% over the past year. SPXC has seen an upward estimate revision for 2026 EPS to $8.41 from $8.06 over the past 30 days. The estimated figure indicates 24.4% year-over-year growth in 2026. SPXC surpassed earnings estimates in all the trailing four quarters, with the average surprise being 8.6%. Again, SPXC’s trailing 12-month return on equity is 16.5%.

Carrier: Headquartered in Palm Beach Gardens, FL, Carrier provides intelligent climate and energy solutions worldwide. Carrier has been benefiting from robust commercial HVAC demand, particularly from data centers, supported by growing hyperscaler and colocation investments and capacity expansion. Growing adoption of liquid cooling provides another opportunity as AI infrastructure becomes more power intensive. 

The recovery in residential and light commercial HVAC, supported by replacement demand and improving channel conditions, adds momentum. In Europe, heat-pump adoption, supportive subsidies, high natural-gas prices and new product launches remain favorable. Carrier is also benefiting from expanding aftermarket opportunities, while the 75F acquisition strengthens its intelligent-building, AI-enabled controls and systems-integration capabilities, broadening its addressable markets.

Carrier currently carries a Zacks Rank #2 (Buy). The stock has lost 11.2% over the past year. Carrier has seen an upward estimate revision for 2026 EPS to $2.85 from $2.79 over the past 30 days. The estimated figure indicates 10% year-over-year growth in 2026. Carrier surpassed earnings estimates in three of the trailing four quarters and missed on the other, with the average surprise being 8.5%.

Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

AI compute is a power problem before it is a chip problem. Hyperscaler capex keeps climbing, PJM capacity prices keep clearing higher, and utilities keep telling the same story: firm, clean, always-on megawatts are the scarce resource. Three US-listed names sit at the pointy end of that thesis, one for each layer of the nuclear stack. Constellation runs the largest US reactor fleet. Talen owns the merchant baseload assets closest to the data center demand curve in PJM. Uranium Energy supplies the fuel from domestic soil.

All three have moved on real catalysts this year, and all three are pricing in different pieces of the same trade.

Constellation Energy: Largest US Nuclear Operator, Raised Guidance Constellation Energy (NASDAQ:CEG | CEG Price Prediction) is trading at $272.88 with a market cap near $96.7 billion and a forward P/E of 23. The Street average target sits at $347.40, with 6 Strong Buy and 14 Buy ratings against 3 Holds. Shares are down 22.41% year to date, compressing the valuation on a company that just raised guidance.

Q2 adjusted EPS of $2.55 beat the $2.3284 estimate by 9.52%, with revenue of $7.504 billion, up 23% year over year. Nuclear output hit 44,160 GWh at a 93% capacity factor. Management lifted full-year 2026 adjusted EPS guidance to $11.50 to $12.50 from $11.00 to $12.00 and reiterated a base EPS growth projection of 20% or more through 2029.

The bull case is contract-backed demand. Constellation has signed 920 MW of 15 to 20-year nuclear PPAs with investment-grade customers, is advancing the Crane Clean Energy Center restart targeting 2027, and filed license renewals for Ginna and Nine Mile Point Unit 1 out to 2049. CEO Joe Dominguez framed the quarter as "strengthening the nation’s energy infrastructure and helping meet growing demand for reliable power." Management said hyperscaler spending for 2026 was tracking "nearly 75% higher than last year and continue to be revised upward." A $5.0 billion buyback authorization with roughly $2.8 billion remaining gives management a lever if the stock stays discounted.

Risk: PJM regulatory rules for large-load interconnection and Reliability Backstop Procurement are still being written, the Illinois ZEC program ends in May 2027, and planned nuclear refueling outage days ran 86 versus 41 a year ago. Calpine integration risk is real given the scale of the January 2026 close.

Talen Energy: PJM Capacity Tailwind and Four-Gigawatt Data Center Pipeline Talen Energy (NASDAQ:TLN) trades at $314.46, down 16.68% over the past month after a messy GAAP print. Market cap sits at $15.07 billion, forward P/E at 13, and the Street’s average target is $465.19 with 6 Strong Buy and 8 Buy ratings.

Q2 headline EPS of -$2.00 missed the $3.3912 estimate, dragged by $211 million in unrealized commodity derivative losses and interest expense that jumped to $214 million from $62 million on $4 billion in new senior unsecured notes funding Cornerstone. Adjusted EBITDA came in at $374 million versus $90 million, versus a year ago, and generation totaled 14.1 TWh. Generation nearly doubled to over 10 GW in the 2028/2029 PJM Base Residual Auction at $325/MWd.

Talen cleared more than 10 GW in the 2028/2029 PJM Base Residual Auction at $2.025 billion to $2.225 billion, raised 2026 adjusted EBITDA guidance to $40 per share, and lifted 2028 base-case free cash flow to 4 GW of land development and data center contracting options. Management flagged approximately 4 GW of data center pipeline options, with the AWS ramp expected to push long-term contracted margin from "leveraging our advantaged portfolio of assets, building our development pipeline of powered land and new capacity all of which allows us to enter into long-term contracts with large loads.". CEO Mac McFarland noted that 30% of 2028 generation is hedged.

Risk: only below 3.5x target of 2028 generation is contracted, leaving Talen exposed to a commodity reversal, and net leverage runs against a target below 3.5x as it digests Cornerstone.

Uranium Energy: Domestic Fuel, Zero Debt, Policy Tailwind Uranium Energy (NYSE:UEC) sits at 31.14% over the past month, up 14.44% on August 21 alone and $6.26 billion. Market cap is roughly $6.26B, and the analyst consensus target implies meaningful upside. This is the upstream exposure: a pure-play US producer with the largest domestic uranium resource base.

Fiscal Q3 produced total cost per pound of $54.61 at a 200,000 pounds at $101 per pound versus a spot average of $80.76, with no revenue recognized as management held inventory. In fiscal Q2, UEC sold 1,456,000 pounds valued at $127 million. Inventory sits at $488 million in cash, backed by $794 million in liquid assets, Burke Hollow began production on April 8, 2026, and zero debt.

The catalysts are strategic. "the largest greenfield ISR uranium project to come into production in more than a decade.", described by management as "the DOE’s ‘Nuclear Dominance: 3 by 33’ initiative, which underscores the urgency of rebuilding a secure, domestic fuel supply chain." CEO Amir Adnani tied the story to Washington policy: Fluor Corporation UEC is also advancing US-based uranium refining and conversion with delayed regulatory approvals and higher Wyoming state taxes.

Risk: single-commodity exposure, no revenue this quarter, and rising per-pound costs. If uranium prices stall, the unhedged strategy cuts both ways.

Different assets, one thesis. Constellation offers scale and contract visibility, Talen offers merchant torque to PJM prices, and UEC offers the fuel. September’s setup gives investors three distinct angles on the AI power buildout to evaluate (we mapped five ways to play the nuclear restart, utilities and fuel included, in a free report here).

Contact [email protected] for any questions or corrections.

Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE:GKOS – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier’s stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of Glaukos during the fourth quarter worth approximately $28,000. Larson Financial Group LLC lifted its position in Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. Parallel Advisors LLC lifted its position in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 226 shares during the period. Farther Finance Advisors LLC grew its stake in Glaukos by 111.4% during the fourth quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 215 shares in the last quarter. Finally, CWM LLC grew its stake in Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Trading Up 0.4% GKOS opened at $185.66 on Monday. The company’s 50 day moving average is $157.38 and its 200-day moving average is $131.72. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $191.62. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue was up 49.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.24) EPS. Equities research analysts predict that Glaukos Corporation will post -0.32 earnings per share for the current fiscal year. Analyst Ratings Changes Several brokerages have recently commented on GKOS. Stifel Nicolaus boosted their target price on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC increased their price target on shares of Glaukos from $150.00 to $201.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (up from $165.00) on shares of Glaukos in a research note on Thursday, July 30th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, UBS Group began coverage on Glaukos in a research note on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $178.08.

View Our Latest Stock Analysis on GKOS

Insider Activity at Glaukos In other news, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the completion of the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,500 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director owned 37,406 shares of the company’s stock, valued at $7,107,140. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 113,025 shares of company stock worth $19,600,006. Corporate insiders own 5.90% of the company’s stock.

Glaukos News Roundup Here are the key news stories impacting Glaukos this week:

Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends. Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale. Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35. Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing Glaukos Company Profile (Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

See Also Five stocks we like better than Glaukos VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. purchased a new stake in shares of AeroVironment, Inc. (NASDAQ:AVAV – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,480,740 shares of the aerospace company’s stock, valued at approximately $574,566,000. BlackRock Inc. owned approximately 6.88% of AeroVironment at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of AVAV. Norges Bank acquired a new position in AeroVironment during the fourth quarter worth $94,655,000. Swedbank AB raised its holdings in AeroVironment by 22,773.4% during the fourth quarter. Swedbank AB now owns 261,214 shares of the aerospace company’s stock valued at $63,185,000 after buying an additional 260,072 shares in the last quarter. Marshall Wace LLP raised its holdings in AeroVironment by 4,770.1% during the fourth quarter. Marshall Wace LLP now owns 260,207 shares of the aerospace company’s stock valued at $62,941,000 after buying an additional 254,864 shares in the last quarter. Heard Capital LLC lifted its position in shares of AeroVironment by 48.4% in the fourth quarter. Heard Capital LLC now owns 722,150 shares of the aerospace company’s stock worth $174,681,000 after buying an additional 235,685 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of AeroVironment by 3,880.9% in the third quarter. Franklin Resources Inc. now owns 206,607 shares of the aerospace company’s stock worth $65,058,000 after buying an additional 201,417 shares during the last quarter. Institutional investors and hedge funds own 86.38% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research analysts have recently commented on AVAV shares. Citizens Jmp lowered their price objective on AeroVironment from $350.00 to $230.00 and set a “market outperform” rating on the stock in a report on Friday, July 10th. KeyCorp restated an “overweight” rating on shares of AeroVironment in a report on Tuesday, July 28th. Citigroup reaffirmed a “market outperform” rating on shares of AeroVironment in a research report on Tuesday, July 28th. Jefferies Financial Group decreased their target price on AeroVironment from $305.00 to $229.00 and set a “buy” rating for the company in a research report on Wednesday, July 1st. Finally, Wolfe Research downgraded AeroVironment to a “buy” rating in a report on Tuesday, June 30th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $266.68.

View Our Latest Stock Analysis on AeroVironment Insider Activity at AeroVironment In other AeroVironment news, Director Stephen F. Page sold 250 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $191.98, for a total value of $47,995.00. Following the sale, the director owned 48,503 shares of the company’s stock, valued at $9,311,605.94. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Brian Charles Shackley sold 205 shares of AeroVironment stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $201.86, for a total value of $41,381.30. Following the completion of the transaction, the chief accounting officer directly owned 7,888 shares in the company, valued at approximately $1,592,271.68. This represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 705 shares of company stock valued at $132,979. 0.79% of the stock is owned by corporate insiders.

Key Headlines Impacting AeroVironment Here are the key news stories impacting AeroVironment this week:

Positive Sentiment: New U.S. drone tariffs could benefit AVAV. President Trump’s August 13 proclamation imposes broad tariffs on foreign drone imports, potentially steering demand toward U.S. manufacturers such as AeroVironment and supporting domestic pricing, production and market share. Trump’s New Drone Tariffs Give AeroVironment, Kratos and Red Cat a Policy Tailwind Positive Sentiment: Greek joint venture expands AeroVironment’s European footprint. AV Eagle, formed with Eyeonix SA, will establish localized production and technology capabilities in Greece after receiving foreign-investment approval. The venture could improve access to European defense programs, strengthen supply-chain resilience and position AVAV to participate in the region’s growing counter-drone market. AeroVironment to Establish Industrial Presence in Greece Through AV Eagle Positive Sentiment: Propulsion investments support longer-term growth. AeroVironment is expanding electric, hybrid and unmanned-aircraft propulsion capabilities, potentially broadening its addressable markets beyond current defense platforms. Clear Street also initiated coverage with a Buy rating, adding to generally favorable analyst sentiment. Can AeroVironment’s Propulsion Capabilities Support Future Growth? Neutral Sentiment: Recent operating momentum remains strong, but valuation is demanding. The latest reported quarter included $641.6 million in revenue, up 133.3% year over year, and EPS of $1.84 versus a $1.47 consensus estimate. However, AVAV remains unprofitable on a trailing basis, trades below its 200-day moving average and carries a high PEG ratio, leaving the stock sensitive to execution and future-growth expectations. Negative Sentiment: Shareholder-law-firm investigations add headline risk. Berger Montague and Grabar Law Office are investigating whether AeroVironment’s board properly disclosed potential competition for U.S. Space Force SCAR program work. The claims are allegations, but any litigation, disclosure findings or related costs could pressure investor confidence. Berger Montague investigates AeroVironment’s board Negative Sentiment: A director’s stock sale is a minor cautionary signal. Director Stephen Page sold 250 shares worth approximately $48,000 under a pre-arranged Rule 10b5-1 plan. Because the sale was small relative to his remaining holdings and scheduled in advance, its direct impact is likely limited. AeroVironment Price Performance AVAV stock opened at $160.22 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 4.30 and a quick ratio of 3.59. AeroVironment, Inc. has a 52-week low of $135.20 and a 52-week high of $417.86. The company has a 50-day moving average of $161.80 and a two-hundred day moving average of $190.00. The stock has a market capitalization of $8.14 billion, a price-to-earnings ratio of -43.54, a price-to-earnings-growth ratio of 5.45 and a beta of 1.41.

AeroVironment (NASDAQ:AVAV – Get Free Report) last issued its quarterly earnings results on Monday, June 29th. The aerospace company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.37. The company had revenue of $641.62 million for the quarter, compared to the consensus estimate of $555.97 million. AeroVironment had a positive return on equity of 3.71% and a negative net margin of 9.00%.The firm’s revenue was up 133.3% compared to the same quarter last year. During the same period last year, the business posted $1.61 earnings per share. AeroVironment has set its FY 2027 guidance at 3.020-3.340 EPS. As a group, equities research analysts anticipate that AeroVironment, Inc. will post 3.26 EPS for the current year.

AeroVironment Profile (Free Report)

AeroVironment, Inc (NASDAQ:AVAV) is a technology company specializing in unmanned aerial systems (UAS), tactical missiles and precision loitering munitions, electric vehicle charging and scalable energy systems. Headquartered in Monrovia, California, the company develops solutions for defense, public safety and commercial markets. Their offerings include small UAS for intelligence, surveillance and reconnaissance, as well as advanced weapons systems designed to meet the needs of modern military operations.

The company’s unmanned aerial systems portfolio features platforms such as the Raven, Puma and Switchblade series, which are deployed by the U.S.

Recommended Stories Five stocks we like better than AeroVironment VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for AeroVironment Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AeroVironment and related companies with MarketBeat.com's FREE daily email newsletter.

Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in shares of AECOM (NYSE:ACM – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,497,153 shares of the construction company’s stock, valued at approximately $383,701,000. Barrow Hanley Mewhinney & Strauss LLC owned about 4.28% of AECOM at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA lifted its stake in shares of AECOM by 86.7% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 280 shares of the construction company’s stock worth $27,000 after buying an additional 130 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of AECOM by 95.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 295 shares of the construction company’s stock valued at $28,000 after acquiring an additional 144 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of AECOM by 189.3% during the second quarter. EverSource Wealth Advisors LLC now owns 298 shares of the construction company’s stock valued at $34,000 after acquiring an additional 195 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new position in AECOM in the 4th quarter worth approximately $38,000. Finally, Western Wealth Management LLC purchased a new position in AECOM in the 1st quarter worth approximately $36,000. Hedge funds and other institutional investors own 85.41% of the company’s stock.

Wall Street Analyst Weigh In Several equities analysts recently issued reports on the company. Zacks Research cut AECOM from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Piper Sandler set a $79.00 target price on AECOM in a report on Wednesday, August 12th. Citigroup decreased their price target on AECOM from $97.00 to $84.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Wall Street Zen downgraded AECOM from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Robert W. Baird dropped their price objective on AECOM from $73.00 to $65.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, AECOM presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.58.

Get Our Latest Research Report on AECOM Insider Activity at AECOM In other news, President Lara Poloni acquired 4,224 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $70.63 per share, with a total value of $298,341.12. Following the completion of the acquisition, the president directly owned 153,446 shares of the company’s stock, valued at approximately $10,837,890.98. The trade was a 2.83% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.46% of the stock is owned by insiders.

AECOM Stock Up 0.1% Shares of AECOM stock opened at $64.88 on Monday. The company has a market cap of $8.35 billion, a price-to-earnings ratio of 29.76, a price-to-earnings-growth ratio of 4.37 and a beta of 0.93. The company’s 50 day moving average is $69.06 and its 200 day moving average is $79.13. AECOM has a twelve month low of $60.35 and a twelve month high of $135.52. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 1.11.

AECOM (NYSE:ACM – Get Free Report) last posted its earnings results on Monday, August 10th. The construction company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($1.96). The company had revenue of $3.59 billion during the quarter, compared to the consensus estimate of $2.01 billion. AECOM had a return on equity of 19.72% and a net margin of 1.87%.The company’s revenue for the quarter was down 14.2% on a year-over-year basis. During the same period last year, the firm posted $1.34 EPS. AECOM has set its FY 2026 guidance at 3.950-4.150 EPS. Research analysts anticipate that AECOM will post 3.98 EPS for the current year.

AECOM Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Wednesday, July 1st were paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date was Wednesday, July 1st. AECOM’s dividend payout ratio (DPR) is 56.88%.

AECOM Profile (Free Report)

AECOM is a multinational infrastructure consulting firm that provides a broad range of professional technical and management services. Its core offerings include architecture and engineering design, program and construction management, environmental remediation and consulting, and operations and maintenance support. The company works across the full project lifecycle from planning and design through construction and long‑term asset management.

AECOM serves public- and private-sector clients in major built-environment markets, including transportation (roads, bridges, rail, airports), water and wastewater systems, buildings and places, energy and power, and environmental services.

Further Reading Five stocks we like better than AECOM VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for AECOM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AECOM and related companies with MarketBeat.com's FREE daily email newsletter.

WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines. 

The launch comes at a time of significant market momentum in oral peptide and biologics development. Pharmaceutical companies continue to invest heavily in oral alternatives to injectable therapies, driven by the potential to improve patient convenience, enhance treatment adherence and unlock new therapeutic opportunities. As a result, pipelines across GLP-1’s, diabetes and weight loss, metabolic disorders, endocrine therapeutics and other peptide-based medicines continue to expand. 

Developers continue to face important challenges as programs move from concept through development and manufacturing, despite growing investment and encouraging clinical progress. Permeability enhancement remains critical for oral drug products, but formulation consistency, process robustness and scalability are increasingly recognized as key barriers to successful commercialization. 

Ashland permexa™ sodium caprate was engineered to help address these challenges by combining established sodium caprate functionality with improved pharmaceutical processing performance. The excipient is designed with an IP-protected process to support more robust tablet manufacturing through improved powder flow, enhanced compressibility and greater formulation consistency, while maintaining the permeability enhancement characteristics required for oral drug delivery applications. The result is a solution intended not only for laboratory success, but also for real-world pharmaceutical development and manufacturing environments where reproducibility, scalability and process robustness are essential. 

The Ashland launch follows strong interest from pharmaceutical developers worldwide. Ahead of the commercial launch, the company recorded engagement with multiple pharmaceutical, biotech and CDMO organizations globally, spanning sampling activities, technical evaluations, pre-launch sales, benchmarking studies and formulation development discussions. Customer feedback has been overwhelmingly positive on the product’s differentiated properties. 

“The rapid growth of oral peptide development is creating demand for excipients that support both biological performance and pharmaceutical manufacturability,” said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. “Permexa™ sodium caprate was engineered to help customers address complex challenges and move more confidently from formulation through commercialization. The level of engagement we have seen prior to launch demonstrates the importance of solutions that support both drug delivery performance and scalable manufacturing.” 

Caroline Cooreman, strategy director, Life Sciences, Ashland, continued, “Consequently, Ashland is not stopping here. We have developed a multi-stage strategy to support the pharmaceutical market with essential excipients for the oral delivery of biologics. We have multiple additional products in the pipeline and recognize important synergies with our vinyl pyrrolidone and derivatives (VP&D) portfolio. We are already actively servicing this market with our established VP&D portfolio, which will be further strengthened by our oral biologics’ portfolio expansion,” she concluded.

For more information about Permexa™ sodium caprate and how the expanded Ashland portfolio of solutions for oral biologics delivery—including product information, technical support and sampling opportunities— interested parties should visit http://ashland.com/permexa  or contact their local Ashland solver. 

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, its strategy as well as the economy and other future events or circumstances.

The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, geopolitical instability and armed conflict, and challenges associated with hiring and managing a diverse workforce across countries with differing laws, regulations, and cultural practices; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, and the inadvertent or accidental disclosure or loss of proprietary or sensitive information; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. “Risk Factors” of Ashland’s most recent Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this presentation.

About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations:Media Relations:Sandy KlugmanCarolmarie C. Brown+1 (302) 594-7777+1 (302) [email protected]@ashland.com Ashland permexa™ sodium caprate Press_Release_Global_Permexa_Launch_FNL_20260824

Ashland permexa™ sodium caprate Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium cap...

 | Source: Martin Marietta Materials, Inc.

RALEIGH, N.C., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (Martin Marietta or the Company) today announced the completion of its previously announced combination with Lhoist North America, Inc. (LNA), a subsidiary of Lhoist Group, on August 21, 2026. LNA is a leading producer of high calcium lime, dolomitic lime and industrial mineral products, serving a diverse range of end markets, including domestic steel manufacturing, infrastructure, heavy nonresidential construction and environmental solutions.

Ward Nye, Chair, President and CEO of Martin Marietta, stated, "We are pleased to announce the successful completion of the LNA combination. This transformative transaction advances our SOAR 2030 objectives by expanding our Specialties platform and further enhancing the quality, scale and resilience of our business. With one of the most strategically advantaged limestone positions in North America, comprised of more than 2 billion tons of high-quality reserves, the combination establishes Martin Marietta as the nation's leading producer of limestone products and strengthens our portfolio of essential upstream materials."

Mr. Nye concluded, "We are excited to welcome LNA and its talented employees to Martin Marietta. Together, we have created a uniquely advantaged portfolio of essential materials supported by industry-leading reserves, strategically located assets and differentiated end-market exposure. As the United States continues to invest in infrastructure modernization, domestic manufacturing and industrial growth, we believe Martin Marietta is exceptionally well positioned to create sustainable long-term value for shareholders."

The Company expects to provide updated full-year 2026 revenue and Adjusted EBITDA guidance reflecting the completion of this transaction in connection with the release of its third-quarter financial results.

About Martin Marietta

Martin Marietta, a member of the S&P 500 Index, is an American-based company and a leading supplier of aggregates, lime and limestone products, magnesia-based products and other building materials. Supported by industry-leading reserves and a network of operations spanning 29 states, Canada and The Bahamas, Martin Marietta supplies the essential materials that help build, connect and sustain communities across North America. For more information, visit www.martinmarietta.com or www.magnesiaspecialties.com.

Investor Contact:
Jacklyn Rooker
Vice President, Investor Relations
+1 (919) 510-4736
[email protected]                                                 

MLM-G.

This press release contains forward-looking statements under the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These statements include: the anticipated benefits of the transaction including increased profitability, synergies and advancement of SOAR 2030 priorities, and costs and other anticipated financial impacts of the transaction. These statements involve risks and uncertainties and are based on assumptions that the Company believes are reasonable, but which may differ materially from actual results, including, among others, risks and uncertainties relating to adverse industry conditions, and potential business uncertainty. These statements reflect the Company’s current expectations or forecasts of future events. You can identify these statements because they do not relate only to historical or current facts and may use words such as “guidance”, “anticipate”, “may”, “expect”, “should”, “believe”, “will”, and other words of similar meaning in connection with future events or future performance. Any or all of the Company’s forward-looking statements herein and in other publications may prove to be incorrect.

Statements regarding the LNA combination contain forward-looking statements that are based on current expectations and assumptions and are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied due to various factors including but not limited to: Martin Marietta’s long-term leverage targets, transaction costs, integration challenges, market conditions, and other risks described in the Company’s Securities and Exchange Commission filings. A further list and description of risks, uncertainties and other matters can be found in Martin Marietta’s Annual Report on Form 10-K for the year ended December 31, 2025 and in Martin Marietta’s subsequent reports on Form 10-Q, including the sections thereof captioned “Other Matters” and “Item 1A. Risk Factors”, and in Martin Marietta’s subsequent reports on Form 8-K. Except as required by law, Martin Marietta does not undertake any obligation to publicly update any forward-looking statements whether as a result of new information, future events, changed circumstances or otherwise.

Deutsche Bank AG acquired a new stake in shares of Zurn Elkay Water Solutions Cor (NYSE:ZWS – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 162,382 shares of the company’s stock, valued at approximately $8,205,000. Deutsche Bank AG owned approximately 0.10% of Zurn Elkay Water Solutions Cor at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Simplicity Wealth LLC purchased a new position in Zurn Elkay Water Solutions Cor in the 2nd quarter worth approximately $368,000. Global Retirement Partners LLC purchased a new stake in shares of Zurn Elkay Water Solutions Cor in the second quarter valued at approximately $151,000. Bank of New York Mellon Corp purchased a new stake in shares of Zurn Elkay Water Solutions Cor in the second quarter valued at approximately $55,207,000. State of Wyoming acquired a new stake in shares of Zurn Elkay Water Solutions Cor in the second quarter valued at approximately $264,000. Finally, S&CO Inc. acquired a new stake in shares of Zurn Elkay Water Solutions Cor in the second quarter valued at approximately $404,000. Institutional investors and hedge funds own 83.33% of the company’s stock.

Insider Buying and Selling at Zurn Elkay Water Solutions Cor In other Zurn Elkay Water Solutions Cor news, Director Jacques Donavon Butler purchased 2,016 shares of the stock in a transaction dated Wednesday, August 19th. The stock was acquired at an average cost of $49.60 per share, for a total transaction of $99,993.60. Following the acquisition, the director owned 37,487 shares in the company, valued at $1,859,355.20. This trade represents a 5.68% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes ZWS has been the topic of a number of analyst reports. Stifel Nicolaus lifted their price objective on Zurn Elkay Water Solutions Cor from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Barclays raised their target price on Zurn Elkay Water Solutions Cor from $59.00 to $61.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Zacks Research upgraded Zurn Elkay Water Solutions Cor from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Weiss Ratings reissued a “buy (b)” rating on shares of Zurn Elkay Water Solutions Cor in a research report on Friday, July 24th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price objective on shares of Zurn Elkay Water Solutions Cor in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Zurn Elkay Water Solutions Cor presently has a consensus rating of “Moderate Buy” and an average price target of $57.22. Get Our Latest Analysis on Zurn Elkay Water Solutions Cor

Zurn Elkay Water Solutions Cor Trading Up 0.2% ZWS opened at $49.10 on Monday. Zurn Elkay Water Solutions Cor has a one year low of $43.06 and a one year high of $55.00. The stock has a market capitalization of $8.14 billion, a PE ratio of 30.31, a P/E/G ratio of 1.85 and a beta of 1.04. The business’s 50 day moving average price is $49.46 and its 200 day moving average price is $48.84. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.13 and a current ratio of 3.05.

Zurn Elkay Water Solutions Cor (NYSE:ZWS – Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.03. The company had revenue of $491.00 million during the quarter, compared to analyst estimates of $483.04 million. Zurn Elkay Water Solutions Cor had a return on equity of 18.01% and a net margin of 15.45%.The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.42 earnings per share. As a group, equities research analysts expect that Zurn Elkay Water Solutions Cor will post 1.82 EPS for the current year.

Zurn Elkay Water Solutions Cor Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, September 4th. Stockholders of record on Thursday, August 20th will be issued a dividend of $0.11 per share. The ex-dividend date is Thursday, August 20th. This represents a $0.44 dividend on an annualized basis and a dividend yield of 0.9%. Zurn Elkay Water Solutions Cor’s dividend payout ratio is currently 27.16%.

Zurn Elkay Water Solutions Cor Company Profile (Free Report)

Zurn Elkay Water Solutions Corp, trading on the NYSE under the ticker ZWS, is a global provider of water delivery and plumbing products. The company was established in October 2022 through a spin-off from Rexnord Corp, creating a standalone business focused on designing, manufacturing and marketing water system components for residential, commercial and industrial customers.

Through its Zurn segment, the company offers solutions for water delivery, drainage and waste evacuation. Product lines include valves, hydrants, backflow prevention devices, piping systems, fittings and commercial waste stations.

Featured Articles Five stocks we like better than Zurn Elkay Water Solutions Cor VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Zurn Elkay Water Solutions Cor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zurn Elkay Water Solutions Cor and related companies with MarketBeat.com's FREE daily email newsletter.

 | Source: Comstock Inc.

VIRGINIA CITY, Nev., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”) today announced it has closed the previously announced transaction under which Mackay Precious Metals Inc. (“Mackay”), a wholly owned subsidiary of Mackay Gold & Silver Corp. (TSXV: MACK, OTCQB: MKGSF), acquired 100% of Comstock's mineral, mining, processing and mining-district-related real estate entities, with the aggregate transaction valued at more than $45 million. Comstock has now received $20 million in cash and 2 million common shares (TSX-V: MACK.V) of Mackay Gold & Silver Corp. currently valued at approximately $4.5 million and we expect to record a gain in a range of approximately $10 million to $12 million. The gain on the sale is not expected to result in any cash taxes.

The transaction included the sale of all four of the Company’s mining subsidiaries – Comstock Mining LLC, Comstock Processing LLC, Comstock Exploration and Development LLC, and Comstock Real Estate Inc. – including all mining claims (patented and unpatented), town lots, processing facilities, operating permits and water rights. Mackay also assumed all of the reclamation obligations and other liabilities associated with the sold entities, along with all associated reclamation and surety bond deposits and collateral.

“This transaction completes another critical objective in our transformation from a hard rock junior mining company into a growing, global, renewable metals and materials company. The transaction enhances balance sheet liquidity, reduces company-wide operating costs and realizes accretive value for our shareholders. This continues our strategy of allocating resources to fund our solar recycling production and growth in a manner that seeks to avoid shareholder dilution,” stated Corrado De Gasperis, Comstock’s CEO. “Closing this transaction simplifies our business, focuses our capacity, and reduces costs while retaining upside through both equity in Mackay Gold & Silver Corp. and future gold and silver NSR royalties.”

A secured, second-tranche payment of $7 million is due within 18 months.

Per the sales agreement, Comstock retains a 1.5% NSR royalty from sales of silver, gold, and all other valuable minerals and products extracted from the sold properties, subject to the terms of the Royalty Agreement which was executed at closing. Mackay has the option to buy out the royalty at any time for $3.5 million in cash. Comstock will further share in the success of Mackay’s exploration and development activities through a contingent payment of $10 million if, within seven years following closing, (i) Mackay makes a decision to proceed with the construction of a mine on any of the properties, or (ii) Mackay is sold, merged, or otherwise participates in a change-of-control transaction with aggregate consideration of at least $500 million. If the contingent payment does not occur, the value of the NSR buy out doubles to $7 million after seven years.

The divestiture will reduce ongoing payroll, permitting, environmental compliance, and related costs for maintaining these mining assets, resulting in an estimated $1.5 million in annual operational savings.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics and renewable fuels and other forms of energy.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
[email protected]

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
[email protected]

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances and business combinations; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings of equity or debt securities; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company or any other issuer.